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Abstract 
Quantitative analysis of the focused ultrasound-induced blood-brain barrier opening with 
applications in neurodegenerative disorders 
 
Maria Eleni Karakatsani 
 
 
The blood-brain barrier poses a formidable impediment to the treatment of adult-onset 
neurodegenerative disorders, by prevention of most drugs from gaining access to the brain 
parenchyma. Focused ultrasound (FUS), in conjunction with systemically administered 
microbubbles, has been shown to open the blood-brain barrier (BBB) locally, reversibly and non-
invasively both in rodents and in non-human-primates. Initially, we demonstrate a monotonic 
increase of the BBB opening volume with close to normal incidence angle, detectable by 
diffusion tensor imaging; the employed contrast-free magnetic resonance protocol that revealed 
the anisotropic nature of the diffusion gradient. Implementation of this optimized BBB opening 
technique in Parkinsonian mice, coupled with the administration of trophic growth factors, 
induced restorative effects in the dopaminergic neurons, the main cellular target of the 
pathological process in Parkinson’s disease. The immune response initiated by the FUS-induced 
BBB disruption has been proven pivotal in reducing proteinaceous aggregates from the brain 
through the activation of a gliosis cascade. Therefore, we investigated this immunomodulatory 
effect in Alzheimer’s disease. The neuropathological hallmarks of Alzheimer’s disease include 
aggregation of amyloid beta into plaques and accumulation of tau protein into neurofibrillary 
tangles. Tau pathology correlates well with impaired neuronal activity and dementia and was 
found to be attenuated after the application of ultrasound that correlated with increased microglia 
activity. Given the beneficial effect of this methodology on the Alzheimer’s pathologies when 
studied separately, we explored the application of FUS in brains subjected concurrently to 
amyloidosis and tau phosphorylation. Our findings indicate the reduction of tau protein and 
decrease in the amyloid load from brains treated with ultrasound, accompanied by spatial 
memory improvement. Overall, in this dissertation, we established an optimized targeting and 
detection protocol, pre-clinical implementation of which confirmed its ameliorative effects as a 
drug-delivery adjuvant or an immune response stimulant. These preclinical findings support the 
immense potential of such a methodology that significantly contributes to the treatment of 
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dopaminergic projections on the AAV+/FUS+ side of the brain. Dendritic densities of the SN 
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staining of the striatum illustrates the ameliorated dopaminergic projections on the AAV+/FUS+ 
hemisphere. Quantitative analysis of the optical density ratio demonstrated significant difference 
(n=4-5; F[3, 17] = 4.733; P=0.014) between the AAV+/FUS+ to the MPTP group. g. 
Amphetamine-elicited behavioral studies revealed more frequent clockwise (toward the 
remaining lesion side) rotation, signifying more prominent dopaminergic function on the 
hemisphere receiving AAV+/FUS+ treatment. ............................................................................ 80 
 
Figure 21: Quantification algorithms. (a) The structural algorithm performed color-based 
segmentation with k-means clustering on the red channel filtering out weaker intensities. The 
Hough transform detected the cells as bright circular objects on a dark background, providing 
their total count and the corresponding coordinates. Singular value decomposition (SVD) was 
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search until an endpoint was reached. The distance of the endpoint to the cell center was 
measured. (b) The intensity algorithm utilized the composite image as input to generate a 
hippocampal mask, omitting the irrelevant neighboring structures. The mask was applied to all 
three channels separately followed by color-based segmentation via k means clustering. For 
every channel the density is reported as the ratio of the pixels belonging to the cluster with the 




Figure 22: Volumetric analysis of the blood-brain barrier opening from the contrast-enhanced 
T1-weighted MR coronal images. The volumes of the transgenic animals were at the order of 
54.8 ± 2.02 mm3, 52.46 ± 6.59 mm3, 54.22 ± 7.44 mm3 and 52.5 ± 5.64 mm3, while 52,83 ± 8.81 
mm3, 54.98 ± 5.97 mm3, 55.48 ± 3.75 mm3and 54.49 ± 9.76 mm3 of the wild-type mice for the 
four consecutive weeks. Longitudinal analysis did not show any significant difference across 
weeks. Additionally, the opening volumes did not differ between transgenic and wild-type 
animals within the same week interval. ........................................................................................ 99 
 
Figure 23: The timeline of the experimental procedure is shown at the top. Briefly, five mice of 
the rTg4510 line at 3.5 months of age were recruited for four sonications, once per week and 
were sacrificed a day after the last treatment. MRI was performed after each sonication to 
confirm targeting accuracy and successful opening. Two slices per transgenic brain were 
counterstained for neuronal cells with the anti-NeuN and anti-β-tubulin ΙΙΙ antibodies along with 
brain slices from a wild-type mouse to assess neuronal integrity. Neuronal compromise could be 
qualitatively observed in transgenic animals compared to healthy mice by the decrease in the 
NeuN signal and the non-uniform signal emitted by the neuronal processes. However, no 
significant differences emerged from the application of ultrasound as shown by the quantitative 
measures. The mean (± standard deviation) neuronal cell density was 39.18 ± 4.25 % and 36.46 
± 3.77%, for the sham contralateral and ipsilateral side while 37.87 ± 4.14% and 39.18 ± 4.09% 
for the corresponding sides of the sonicated brains. Respectively, the mean value (± standard 
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Figure 24: The timeline of the experimental procedure. For this immunohistochemical analysis 
brain slices from the transgenic animals were counterstained for phosphorylated tau with the 
AT8 antibody and immune cell activation with the CD68 antibody while imaged by confocal 
microscopy. (b) Representative composite images of the sham and sonicated ipsilateral 
hemispheres are shown with the red channel corresponding to the signal emitted from 
phosphorylated tau, the green channel reflecting the immune response and the blue channel 
representing the cell-dye Hoechst 33342. (c) Bar scatter plot representation of the samples 
showing a significant reduction in the p-tau signal when comparing the hemispheres of the sham 
and the sonicated brain. In particular, we observed a reduction in the p-tau signal on the order of 
57.35% (F[1,8] = 34.32;P=0.0004) when comparing the contralateral hemispheres of the sham 
and the sonicated brains, while 72.65% (F[1,8] = 34.32;P<0.0001) when comparing the 
ipsilateral hemispheres. (d) On the other hand, the total cell numbers detected by the algorithm 
did not differ among the groups or the hemispheres (e) Immune cell activation was confirmed by 
the signal obtained from the CD68 marker. Immune system upregulation was expected due to 
pathology but a 54.41% increase (F[1,8] = 46.4;P<0.0001) was observed in the hemisphere 
treated with ultrasound while a 41.6% (F[1,8] = 46.4;P=0.0064) increase in its contralateral side 
compared to the control brains. (f) Regression analysis between the p-tau signal and the immune 
cell activation yielded a significant deviation of the slope from the zero value suggesting a 
correlation between the two parameters (r2=0.3285; β=-2.136; P<0.0001). Scale bar, 100μm. 104 
 
Figure 25: (a) Phosphorylated tau signal emitted from the affected pyramidal neurons of the 
ipsilateral and contralateral side in the CA1 sector of the sham and sonicated brains. (b) 
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Comparison of the cumulative density function (CDF) of the p-tau processes length as obtained 
from each group (sham contra, sham ipsi, sonic contra and sonic ipsi). This graph describes the 
probability (y-axis) of finding p-tau processes of a certain or smaller length (x-axis). The 95th 
percentile (upper red line) crosses the CDF of the sonicated ipsilateral side at 300μm (dotted red 
line), while at 700μm (dotted red line) for the untreated brain. This finding suggests that the 
probability of finding a p-tau neuronal process equal or smaller than 300 μm in the sonicated 
brain and 700μm in the unsonicated brain is 0.95. (c) The cumulative density function of the 
difference in p-tau processes length between the sham and sonicated hemisphere (ipsi sham-ipsi 
sonic). The zero crossing denote the probability of p-tau processes having the same length 
between the two hemispheres. From this CDF it can be observed that 68% of the neurons on the 
sham ipsilateral side are longer than those on the sonicated ipsilateral side. Scale bar, 100μm. 107 
 
Figure 26: Microglia colocalization with phosphorylated tau protein. For this 
immunohistochemical analysis, two brain slices from the transgenic animals were counterstained 
for phosphorylated tau and microglia presence with the AT8 (red) and the Iba1 (green) antibody. 
Three Z-stack series were captured on a 60x objective covering the CA1 region. (a-d) Qualitative 
evaluation of the biomarker colocalization. The three planes, XY (main), XZ and YZ 
(orthogonal) are presented for a microglia cell. The images are magnified versions of the 60x 
objective and the corresponding video included in the Supplementary Material. (a, c) The 
microglia are shown to verge on the phosphorylated tau but not engulf it as indicated by the lack 
of the channel overlap in all three planes. (b, d) The microglia seem to engulf fragments of 
phosphorylated tau after the application of ultrasound in both hemispheres of the sonicated 
brains. The overlap of the two channels is consistent in all three planes. (e-h) The four panels 
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follow the same structure: a composite image showing the merged and monochromatic images of 
the isolated CA1 sector and the scatterplot of the two channels. The scatterplot colormap 
indicates the pixels density. (e) The neuronal processes are largely affected by phosphorylated 
tau while the presence of microglia is evident in the ipsilateral sham hemisphere. The scatterplot 
has a slope (the slope obtained by performing linear regression between the two channels) of 
0.022 suggesting that more pathological tau is present (higher red channel values) than microglia 
(smaller green channel values) while Pearson’s correlation coefficient (PCC) is 0.0345 
suggesting minor statistical dependence between the biomarkers. (f) The sonicated hemisphere 
experienced a reduction in phosphorylated tau and an increase in microglia presence indicated by 
the higher value of the fitted slope equal to 0.207, while the PCC increased for this case to 0.068. 
(g) Similar findings to the ipsilateral hemisphere can be extracted from the contralateral sides 
where the slope is 0.038 and the PCC of 0.058 in the sham brain while (h) the slope reached 
0.122 and the PCC 0.0.068 in the sonicated brain. (i-l) Cumulative results on the dependency 
metrics. Comparable PCC values suggest that ultrasound did not affect the covariance of the two 
biomarkers. However, a significant increase in the slope of the linear regression line by 43% can 
be observed between the ipsilateral hemispheres (F[1.6]=6.214;P=0.047). Furthermore, the 
percent of red-to-green channel contribution, measured here my Manders’ M1 overlap 
coefficient, increased significantly by 43% (F[1.6]=162.5;P<0.0001) while the M2 coefficient 
decreased significantly by 36% (F[1.6]=258.9;P<0.0001) suggesting greater overlap of the green 
with the red channel in the ipsilateral hemisphere. Similarly, M1 overlap coefficient increased by 





Figure 27: Repeated sonications improve spatial memory in transgenic and non-transgenic mice: 
A. The schematic of the Morris Water Maze setup that was used to behaviorally examine the 
animals in respect to their spatial memory functionality. The circular maze is considered to 
consist of four quadrants, the target, the opposite and the adjacent. B. Learning curves of the 
escape latency and the distance traveled to find the hidden platform are presented herein and 
plotted against the days of training. Both the distance traveled (F[4,144] = 15.57; P < 0.0001) 
and the escape latency (F[3,36] = 7.542; P = 0.0005) significantly deteriorated for the sham 
transgenic animals the last day of the training while all other groups continued to improve. C. 
Representative individual heatmaps of the time spent in every quadrant followed by the 
cumulative results on the probe trial. The sham transgenic animals did not show preference over 
any quadrant while the sonicated transgenic animals spent significantly more time in the target 
quadrant (F[1.637, 16.37] = 4.051; P = 0.044). Respectively the non-transgenic mice spent more 
time in the target quadrant with the sonicated group at a much higher percentage (sham non-
transgenic: F[1.965, 17.68] = 6.375; P = 0.0085, sonicated non-transgenic F[1.776, 15.99] = 
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Figure 28: Repeatability of FUS-induced BBB opening and association with behavioral 
outcomes in the transgenic animals. The BBB opening volume was measured on the order of 
57.5 ± 8.3 mm3, 51.4 ± 12.5 mm3, 51.00 ± 9.3 mm3 and 46.3 ± 14.2 mm3 for the four weeks 
respectively. Statistical analysis revealed comparable opening sizes across weeks. Regression 
analysis between the cumulative BBB opening volume and the time spent in the target quadrant 
showed a linear relationship (r2 = 0.42) with a significant deviation of the slope from the zero 
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value (slope=0.3941; F[1.9] = 6.43; P = 0.0319). Brain schematics were constructed using Brain 
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Figure 30: Human total tau quantification. A. Immunohistochemical analysis of the hHT7 
antibody detecting human total tau protein  revealed a decrease of the neuronal processes 
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Figure 31: Microglia activation in different sonication regimes. All animals were sacrificed 24 h 
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the microglia processes’ length and the number of endpoint showed a decrease indicative of 
activation. B. Sonication within the “safety window” results in microglia activation shown 
qualitatively and quantitatively. C. Animals were sonicated at 150 kPa without a detectable BBB 
opening. However, the activation of microglia follows the same trend as in the BBB detectable 
groups, A and B. D. Sonication in the absence of microbubbles at 1 MPa resulted in the 
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Chapter 1. Background and Motivation 
1.1 Central nervous system barriers 
The central nervous system (CNS) integrates and coordinates information received from all parts 
of the body through its main structures, the brain and the spinal cord. The architectural 
characteristics of the CNS microvessels are uniquely suited to preserve ionic homeostasis1 by 
formation of brain-barrier interfaces that restrain diffusion2. Molecular exchange between the 
blood and the brain (interstitial fluid and cerebrospinal fluid (CSF)) is regulated through tight 
junctions3 by i. the blood-brain barrier in the neurovascular unit (Figure 1a), ii. the blood-CSF 
barrier at the choroid plexus (Figure 1b), iii. the arachnoid barrier between the subarachnoid 
space and the dura in the middle of the meninges (Figure 1c) and iv. the PIA/glia limitants 
barrier between the CSF and the extracellular fluid of the brain (Figure 1c). Of the various CNS 
barriers, the toughest compartmental control over the immediate microenvironment is exerted by 
the blood-brain barrier (BBB)2–4. 
 
1.2 The blood-brain barrier 
The anatomical substrate of the BBB, the cerebral vascular endothelium, along with pericytes, 
microglia, astrocytes and neurons constitute the neurovascular unit that encompasses a wide 
range of morphological characteristics and functional features. Cerebral endothelial cells lining 
the brain vessels circumferentially restrict diffusion by complex tight junctions, forcing 
molecular trafficking to take a transcellular route rather than paracellular2–5 (Figure 2). The tight 
junctions are intricate transmembrane and cytoplasmic proteins6 whose tightness is reflecting the 
permeability of the BBB. BBB permeation can occur through lipid membranes for small 
lipophilic molecules such as O2 and CO2, specific transport systems for nutrients among other 
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hydrophilic agents or metabolic transport by a combination of intracellular and extracellular 
enzymes7. 
 
Figure 1: The central nervous system barriers. a. The blood-brain barrier between the 
brain parenchyma and the blood lumen. b. The blood-CSF barrier at the Choroid plexus. 
c. The meningeal barriers consisted of the arachnoid barrier between the CSF in the 
subarachnoid space and the overlaying structures, as well as the PIA/glia limitants barrier 
and the brain parenchyma. d. The CSF-brain barrier is important only in the embryo 
while it is governed by free exchange in the adult brain4. 
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Large hydrophilic compounds necessitate receptor-mediated trancytosis. Attached to the 
abluminal part of the endothelium are the pericytes, cells necessary for the functionally effective 
BBB formation. Moreover, pericytes regulate tight junctions, vesicle transportation and the BBB 
permeability by inhibition of adhesion molecules increasing vascular permeability. The basal 
lamina of the endothelial cells is enseathed by the astrocytic end feet that mediate the induction 
of phenotypic BBB features6,7. Although astrocytes vary morphologically in regards to their 
location and cell association, 72% of the population interacts with the BBB features resulting in 
the tightening of the junctions, expression and localization of enzymes and transporters6,7. 
Neurons innervate the vascular endothelium or the astrocytic processes or can be found in their 
near proximity, no further than 10 μm7. Neuronal activity and the associated metabolic needs are 
met by the highly responsive microcirculation6. Finally, microglia are innate immune cells highly 
responsive to the blood-brain barrier by surveillance of their microenvironment. BBB 
dysfunction or infiltration of infectious agents in the brain parenchyma can morphologically alter 
their phenotype and properties. Synergistic functions involving more than one of the 
aforementioned cell types are a highly plausible scenario given the complexity of the barrier 
properties6. 
 
The transport mechanisms discussed allow the BBB to control the efflux and supply of the brain 
with nutrients by restricting ionic and fluid exchange between the two compartments involved, 
providing ideal conditions for neuronal function. Furthermore, the BBB protects the brain from 
ionic fluctuations while preserving the separation of peripherally and centrally derived 
neurotransmitters or neuroactive material. Homeostatic stability can be disturbed though, in the 
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1.3 Neurodegenerative disorders 
In spite of the broad use of the term “neurodegeneration’, the precise definition is yet an arduous 
effort8. In practice, neurodegeneration encompasses disorders related to the impairment of 
neurons in specific functional anatomic systems among which, Parkinson’s (PD) and 
Alzheimer’s disease (AD) belong to the lion’s share of attention along with amyotrophic lateral 
sclerosis and Huntington disease. Despite the complexity, classification of the neurological 
disorders can be performed based on the predominant clinical feature or the topography. Here, 
we focus on the two major age-related and chronically progressive neurodegenerative disorders 
affecting different neuronal networks, Alzheimer’s and Parkinson’s disease. 
 
1.3.1 Alzheimer’s disease 
Alzheimer’s disease is the most common age-related and chronic neurodegenerative disorder 
characterized histopathologically by the accumulation of insoluble forms of amyloid-β (Aβ) in 
plaques and the aggregation of hyperphosphorylated forms of the microtubule-associated 
protein-tau into neurofibrillary tangles (NFT) in neurons9,10 (Figure 3). Extensive research 
reports that these two hallmark lesions, and the accumulation of toxic intermediates from which 
they are formed, are implicated in the initiation and progression of dementia. The amyloid 
cascade hypothesis11 suggests that Aβ promotes tauopathy which has been demonstrated in 
numerous experiments. The pathological cascade of events that leads to tauopathy and 
neurodegeneration includes tau hyperphosphorylation, misfolding and aggregation, 
destabilization of the microtubule network and the cytoskeleton, deficits in axonal transport, 
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form the nigrostriatal pathway (Figure 4), whereas loss of neurons in the Substantia Nigra pars 
compacta (SNpc) results in striatal dopamine deficiency19. In advanced stages of PD, non-motor 
symptoms become a significant part of the disease, including cognitive impairment, psychiatric 
and autonomic dysfunction that can often become more troublesome than the cardinal motor 
manifestations of PD20. These disabling non-motor manifestations have been attributed to the 
degeneration of non-dopaminergic pathways that arises over the course of the disease21 and 
which are typically not responsive to either dopaminergic therapies (e.g. L-DOPA 
administration) or deep brain stimulation. Conversely, in early stage PD, patients are highly 
responsive to dopaminergic stimulation21. This is particularly important as patients with early PD 
are physically and professionally active22 and most are reticent to use L-DOPA because of its 
known site effects. From a clinical standpoint, the cornerstone in prevention and management of 
the disease is the deceleration of the progression through non-pharmacological approaches -
behavioral techniques and adjusted nutrition- and pharmacological agents targeting cognition 
enhancement and systemic complications management. Despite the importance of symptomatic 
amelioration, the development of a disease-modifying drug remains a priority. 
 
1.4 Focused ultrasound 
Treatment of the CNS diseases involves the engagement of the blood-brain-barrier to transport 
therapeutic agents to impaired brain structures. The BBB hinders the transcellular diffusion path, 
which is confined only to lipid soluble compounds smaller than 400 Da with fewer than nine 
hydrogen bonds crossing via lipid-mediated transport. To overcome this obstacle, current 
treatment strategies involve transcranial injection or infusion, trans-nasal delivery or 
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The microbubbles are perfluorocarbon-filled, lipid-coated microspheres on the order of a few 
microns in diameter, characterized by slow solubility and dissolution kinetics, attributed to their 
shell composition28. The lipids form spontaneously a monolayer coating, with their hydrophobic 
tails facing the gas core, when their aqueous suspension is dispersed with perfluorocarbon and 
acoustically emulsified29. Their stability in the blood vessels has been improved by increasing 
the hydrocarbon chain-length of the coat-constituent lipids improving their physicochemical 
properties and their overall efficiency28–31. 
 
The acoustic transducer is a piezoelectric element generating an acoustic pressure wave when 
electric energy drives it. Ultrasonic energy focused at the geometrical center can be tightly 
deposited deeply within the brain tissue while minimizing skull energy absorption. During 
focused ultrasound application the transmitted acoustic pulse generates a radiation force that 
drives the expansion and contraction (or collapse) of the microbubbles following the respective 
periodic cycles of rarefaction and compression30. Acoustic cavitation describes the volumetric 
oscillations of the microbubbles that in turn deform the compliant boundary of the nearby vessel 
walls. Controlled oscillation of the microbubbles, stable cavitation, results in increased vascular 
permeability, while rapture of the bubbles, inertial cavitation32, has been associated with 
increased risk for damaging the surrounding microenvironment32,33.   
 
Hence the size-dependent resonance behavior of the microbubbles, their response to the acoustic 
field varies according primarily to the center frequency, the applied pressure and the pulse 
length28. To compromise the tradeoff between irreversible cavitational effects at low frequencies 
and strong attenuation effects at high frequencies, the optimal frequency for transcranial 
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applications has been placed in the range of 0.2-1.5 MHz34–36. The relatively low frequencies 
combined with various pressures have been shown to successfully induce BBB openings of 
different sizes depending on the weight of the deliverable agent35. Moreover, pairing lower 
pressures with longer pulse lengths has been found to induce similar opening sizes to higher 
pressures with shorter pulse lengths37. The effect of the ultrasound parameters on the vascular 
permeability is linearly dependent on the microbubble concentration while the functional 
outcomes are more predictable for narrower size-distributions of microbubbles34. 
 
The closing timeline and the reversibility of the BBB opening have been extensively investigated 
to assess the safety profile of the intervention. The time necessary for the barrier to be fully 
restored has been found proportionally related to the opening volume assuming the induction of a 
single opening38. Decoupling of this dependence has been achieved by substituting large 
openings with small multi-foci openings decreasing the necessary time for the barrier to be 
restored39,40. Longitudinal studies on rodents and primates have shown that repeated ultrasound-
induced BBB opening in the absence of vascular damage is a transient and reversible 
application41,42.  
 
Passive cavitation detection (PCD) captures the acoustic emissions from the oscillating 
microbubbles providing information regarding the cavitation signature43. Accurate expectation of 
the induced BBB opening volume has been achieved through its association with the 
corresponding cavitation levels43. Passive cavitation mapping expanded the single dimension of 





Although passive cavitation detection is a promising modality in spatially associating 
microbubble oscillations with BBB opening44,45, the gold standard in confirming the occurrence 
of an opening, validating the accuracy of the targeting and assessing the barrier’s restoration in 
vivo is contrast-enhanced T1-weighted magnetic resonance imaging (MRI)26,46. T1-weighted 
imaging after the injection of contrast agents incapable of naturally crossing the BBB are 
employed as tracers to spatially localize the disruption site. Contrast agents are useful in the 
quantification of the BBB opening volume based on their diffusion area while their permeability 
changes over time provide information for mapping their transfer rate 47,48. T2-weighted imaging 
and susceptibility weighted imaging (SWI) have been extensively employed to assess potential 
edematous or inflammatory regions and hemorrhagic, respectively, following FUS application41. 
 
Restoration of the barrier has not been only macroscopically evaluated by MRI but also 
neurologically by visual, cognitive, motivational and motor function behavioral testing41,42. 
Although the interaction of systemically-administered microbubbles with the capillary walls has 
been proposed to drive the disruption of the BBB with FUS, the mechanism is not entirely clear 
as not fully understood are the downstream bioeffects. Disassembling of the tight junctional 
(TJs) molecular structure has been placed at the beginning of the induced biological cascade, 
explaining the paracellular passage of molecules that has been reported49,50. Moreover, 
transcriptomic analysis in the acute stages following sonication revealed a transient upregulation 
in proinflammatory cytokines and chemokines including CCL2, CCL3, and Tnf that have been 
found to promote migration, proliferation, differentiation and survival of neural progenitor cells 
favoring neurogenesis51. Prominent presence of BrdU-positive cells in animals that survived for 
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a week after the last of six sonications has been linked to enhanced neurogenesis attributed to the 
expression of trophic factors such as brain-derived neurotrophic factor in the targeted brain52. 
Concurrent with the overexpression of inflammatory markers that mostly resolved within 24 
hours, was the increase in angiogenetic-related genes and astrocytic activation51.  
 
Despite the positive impact of the technique, reports on elevated microtubule-associated protein 
tau, phosphorylated at the Thr231 epitope52, and activated Nf-κB pathway53 following repeated 
sonications, alarmed the ultrasound field and surfaced important unmet needs. Although the 
uncontrolled phosphorylation of tau protein has been linked to Alzheimer’s disease, 
phosphorylation has to occur at specific epitopes and proven to lead to pathological outcomes54. 
Tau phosphorylation at the Thr231 epitope is associated with both physiological and pathological 
processes54 and further experimentation is required to assess association with Alzheimer’s 
disease as the upregulation alone does not suffice. Regarding the initiation of the Nf-κB pathway, 
several reports argue on whether it is a byproduct of the sonication regime53 or it is completely 
dissociated from the intervention51. Contradictory findings and ambiguous interpretations signify 
the need to fully characterize the biological changes specific to the selected sonication protocol.  
 
So far, FUS has been studied extensively in a multitude of experiments involving the safe 
disruption of the BBB of various animal species (including rabbits55,56 mice57, rats58 and 
primates59,60) and in different animal models61–67. The integrity of the BBB is restored within 
hours and it remains intact68 depending on the ultrasound parameters, regardless of the 
pathological state of the brain at least for early stages69. FUS mediated BBB opening has been 
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proven indifferent in terms of energy requirements to achieve permeability and closing timeline 
between transgenic and wild type mice69.  
 
This intervention has shown efficacy in delivering various compounds of different molecular 
weights into the brain parenchyma including contrast agents37, sugars70, antibodies71, 
chemotherapeutics72 and neurotrophic factors66,67,70,73–76. FUS-induced BBB opening was 
initially introduced as a surrogate to drug delivery techniques. It prevailed due to its non-invasive 
and targeted principles. 
 
Aside from facilitating drug delivery, FUS-induced BBB opening has been introduced as an 
immunomodulatory stimulant associated with microglia activation53 following a unique cascade 
that strongly depends on the ultrasound parameters (Figure 5). More importantly, it has been 
observed that FUS-induced BBB opening over the entire brain activated microglia leading to the 
52% reduction of amyloid burden62. This important finding highlights the potential of inducing a 
beneficial immune response by ultrasound, using a safely tolerated paradigm61,62. Such 
observations re-introduced the FUS-induced BBB opening as an immunomodulatory stimulant. 
Microglia are self-proliferating resident cells, well integrated in the neurovascular unit in the 
healthy brain77. Preservation of homeostasis is performed during their “resting state” by a 
scavenging function of the immediate neighborhood with the cell somas remain relatively stable 
while the processes undergo dynamic elongation and retraction to monitor the environment 
(Figure 5). Upon detection of a pathogen or alteration of the homeostatic status, microglia 
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modulation of microglia and monocytes’ recruitment can have a profound beneficial effect in 
ameliorating neurodegeneration while pointing towards the notion that the inflammatory 
environment impacts negatively the microglia to engage in their phagocytic role81. There is an 
immense potential in studying microglia functionality beyond their phenotypic changes80. 
Whether FUS-induced BBB opening drives a “healthy” activation of microglia, or infiltrating 
blood-derived macrophages82 help ameliorate such pathologies remains unclear but these 
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Chapter 3: Optimization of the focused ultrasound targeting and the 
blood-brain barrier opening detection. 
In this chapter, a thorough optimization maximizing the targeting efficiency in sonications 
employing single element transducers will be described followed by the exploration of contrast-
free MRI to overcome the deleterious effects of Gd retention in the brain tissue. 
 
3.1 Targeting effects on the volume of the focused ultrasound-induced blood-brain 
barrier opening in non-human primates in vivo. 
3.1.1 Abstract 
Drug delivery to subcortical regions is susceptible to the BBB impeding the molecular exchange 
between the blood stream and the brain parenchyma. Focused ultrasound coupled with the 
administration of microbubbles has been proven to open the BBB locally, transiently and non-
invasively both in rodents and in Non-Human-Primates (NHPs). The development of this 
disruption technique independent of MRI monitoring is of primordial importance yet restrained 
to the targeting optimization. The current paper establishes the linear relationship of the 
incidence angle with the volume of BBB opening (VBBB) and the Peak Negative Pressure (PNP) 
when sonicating the Caudate Nucleus and the Putamen region of five non-human-primates. In 
addition, the effect of central nervous system structures on the opening morphology is evaluated 
by identification of the gray-to-white-matter ratio at the opening site. Finally, the targeting 
accuracy is assessed through estimation of the geometric and angle shift of the opening from the 
targeted region. Interestingly, results prove a monotonic increase of the opening volume with 
close to normal incidence angles.  Moreover, 80.35% of the opening lies on gray matter regions 
compared to only 19.41% attributed to the white matter. The opening was found to be shifted 
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axially, towards the transducer, and laterally with an average angle shift of 4.5°. Finally, we were 
capable of showing reproducibility of targeting accuracy with the same stereotactic and 
ultrasonic parameters. This study documents the a priori prediction of the opening volume 
through manipulation of the angle and pressure as well as establishing the predictability, 
accuracy and safety of FUS induced BBB opening in NHPs. 
 
3.1.2 Introduction  
The mechanism of BBB disruption with FUS is not entirely clear, however, it has been proven 
that the BBB can be mechanically disrupted by cavitation occurring from the oscillating 
microbubbles that pass through the focus of the ultrasound beam27,69,86. Extensive research has 
been conducted to evaluate the microbubble properties affecting the BBB in the presence of 
ultrasound. The BBB opening volume has been shown to increase with concentration and 
microbubble size while small increases in the microbubble phospholipid chain length resulted in 
more efficient delivery of large molecules31,87,88.   
 
The transition from bench to bedside requires precise selection of parameters that would 
guarantee targeting accuracy, repeatability and safety. Several studies have been focused on the 
optimization of the acoustic parameters on various animal models including, mouse, rabbit and 
non-human primate aiming at safe and localized openings43,89–95.  While traversing from mouse 
to NHP, the parameters to be determined in terms of brain complexity and experimental setup 
increase. Furthermore, the targeting accuracy in NHPs is susceptible to skull aberrations.  When 
sonicating NHPs, the preference of intermediate ultrasound frequencies around 500 kHz 
eliminates the tradeoff between irreversible cavitational effects and increased focus at lower 
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frequencies and high phase aberrations and attenuation at higher frequencies43,96–98. Yet the 
frequency is not the only factor that could result in vascular damage as PNP is of equal 
contribution and importance. It has been reported that increased PNP yield larger openings in a 
linear trend while shorter pulse lengths and intermediate pulse repetition frequencies (PRFs) are 
preferred33,94,96,99.  However, PNP to opening volume correlations in NHP’s yielded very low 
determination coefficients while the cross correlation among animals was 
inconclusive33,97,98,100,101.  It has been shown that the normal incidence angle yields larger 
openings but its relationship with the opening size and the PNP is yet to be established102. The 
necessity to alter the angle rose from the complexity of the NHP brain and the aim to avoid 
affecting neighboring areas and vascularized regions. Despite taking into account the angle, 
however, agreement across animals remains elusive. Therefore, the skull effect was investigated 
as of affecting the energy propagating to the targeted region. According to the incidence angle of 
preference, the beam propagates through a varying skull volume resulting in subsequent pressure 
alterations102–104. Moreover, inter-animal skull variation adds to the complexity of the problem. 
The targeting accuracy subjected to the variation of these parameters has to be optimized before 
moving on to clinical trials.  
 
In this study, we seek to provide insight into the uncorrelated results within and among animals 
by: (i) establishing the relationship between the incidence angle and the BBB opening volume, 
(ii) employing the skull effect as the correction factor among animals and (iii) evaluating the 
brain structures’ effect on the opening morphology. The skull effect was evaluated at different 
incidence angles and was utilized as the correction factor to the results while the percent of gray 




3.1.3 Materials and Methods  
In vivo experiments 
The ultrasound procedure was performed in five male NHPs, i.e. four rhesus macaques (Macaca 
mulatta) and one marmoset (Callithrix jacchus) allowing for a minimum of two-week resting 
period before subsequent treatment. During each procedure, the animals were immobilized by 
intramuscular administration of a cocktail containing 1ml ketamine (5-15 mg/kg) and 1ml 
atropine (5-15 mg/kg) to provide a time window for endotrachial tube placement, catheterization 
and positioning on the stereotaxic frame. While in the operation room, the animals were 
anesthetized by inhalation of 1–3% isoflurane. The transducer was attached to the Kopf 
stereotaxic manipulator to allow for targeting the brain in the stereotaxic coordinate frame, the 
cornerstone of the targeting analysis. The animals were transferred to the MRI site after the 
sonication for assessing the safety of the method and verifying the BBB disruption. 
 
Focused ultrasound 
The sonications were carried out by a single-element, spherical-segment FUS transducer (H-107, 
Sonic Concepts, Bothell, WA) operating at 0.5 MHz (radius: 32 mm; geometric focal length: 
62.6 mm, focal length: 34 mm and focal width: 5.85 mm), under the application of a function 
generator (Agilent, Palo Alto, CA, USA) through a 50-dB power amplifier (E&I, Rochester, NY, 
USA). A flatband, spherically focused hydrophone (Y107, Sonic Concepts, WA, USA; 
sensitivity: 10 kHz to 15 MHz; focal depth: 60 mm, radius 19.75 mm) was confocally mounted 
at the central void of the transducer to achieve overlap of the two foci. The hydrophone was 
driven by a pulser–receiver (Olympus, Waltham, MA, USA) connected to a digitizer (Gage 
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Applied Technologies, Lachine, QC, Canada). The acoustic beam profile and the -6 dB focal 
zone were measured during the calibration process accomplished by the use of a needle 
hydrophone (HGL-0400, Onda, Sunnyvale, CA, USA). According to previous reports100–104, the 
global attenuation due to absorption, reflection and scattering phenomena resulting from the 
skull thickness was estimated to be equal to 4.92 dB/mm at the center frequency. In-house 
manufactured, lipid-shell, monodisperse microbubbles with a mean diameter of 4 to 5 μm were 
diluted to 2×105 # bubbles/mL. The microbubbles at a dosage of 2.5×108 # bubbles/kg were 
intravenously injected through the saphenous vein 10 sec after the onset of sonication to allow 
for real-time monitoring of the microbubble cavitation described elsewhere29. The animals were 
sonicated in one or two locations for 120 sec each, allowing a 20-minute waiting period for 
microbubbles to be cleared from the circulation, at a pulse repetition frequency (PRF) of 2 Hz, 
pulse length of 10 ms and PNP varying from 0.25 MPa to 0.6 MPa. 
 
Targeting 
Individualized targeting of the ultrasound focus to the brain region of interest was accomplished 
by employment of a Kopf stereotaxic instrument. The system provided the user with 9 degrees of 
freedom; the medio-lateral drive (ML), the stereotaxic arm along the anterior-posterior (AP) 
direction oriented perpendicularly to the ML drive, the manipulator determining the dorso-vetral 
(DV) setting oriented perpendicularly to the ML-AP plane, the rotation of the manipulator 
around the DV-axis (azimuth), the rotation of the manipulator around the ML- or AP- axis 
(elevation), the selection of right or left stereotactic arm (arm), the relative alignment of the ML- 
and DV- drives (stereo) and finally the attachment of the transducer to the stereotactic 
manipulator (finger). In order to predict and evaluate the targeting accuracy, the geometric 
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characteristics of the stereotactic device were analytically implemented into a custom algorithm 
in MATLAB based on the relative positioning of the nine aforementioned parameters in terms of 
the stereotaxic coordinate frames. This routine yielded the coordinates of the focal spot and the 
surrounding ellipsoidal area denoting the focal region in the global coordinate system translated 
into spatial domain by superposition onto the stereotactically aligned T1-weighted scan 
accounting for the reference scan for each NHP. 
 
Opening verification with MRI 
Magnetic resonance imaging was employed to verify the opening and detect potential damage. 
High-resolution structural T1-weighted sequences (T1 Pre; 3D Spoiled Gradient-Echo, TR/TE = 
20/1.4 ms/ms; flip angle: 30°; NEX = 2; spatial resolution: 500 × 500 μm2 ; slice thickness: 1 
mm with no interslice gap) were acquired at two time-points for each NHP, before and after 
BBB opening. The first scan was acquired 30 minutes after IV administration of 0.2 ml/kg Gd 
(gadodiamide), as the contrast agent, without preceding sonication accounting as the pre-
sonication scan for each NHP while the second scan was acquired after each sonication 
corresponding to the post-sonication scan. Gd does not naturally cross the intact BBB because of 
its molecular size exceeding the threshold (400 Da) and solubility pattern and therefore was 
utilized as a means of visualizing vessels or structures with increased BBB permeability 
attributed to hyperintense pixelation. Prior to the sonications, a structural T1-weighted sequence 
of the same acquisition parameters but spatial resolution of 250 × 250 μm2 was obtained while 
the animal was positioned on the stereotactic frame accounting for the reference image. 3D T2-
weighted sequence (TR/ TE = 3000/80 ms/ms; flip angle: 90°; NEX = 3; spatial resolution: 400 
× 400 μm2 ; slice thickness: 2 mm with no interslice gap) and 3D Susceptibility-weighted 
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imaging (SWI) (TR/TE = 19/27 ms/ms; flip angle: 15°; NEX = 1; spatial resolution: 400 × 400 
μm2 ; slice thickness: 1 mm with no interslice gap) were utilized to detect edematous and 
hemorrhagic regions if any60,105.  
 
Data analysis 




The targeting pipeline yielded the focal area, the incidence angle and the skull thickness scaling 
factor. The input values to the algorithm were limited to the nine parameters utilized for the 
stereotactic configuration at the sonication site and resulted in the vector of axial propagation and 
the focal area after the application of linear transformations. To visualize the targeting on the 
monkey brain, the resulting ellipsoidal shape was projected on the reference T1-weighted image 
as shown in Figure 9b. The information provided by this step was used to estimate the focal area 
and the center of the focus (Figure 9c). The next step was the skull extraction from the reference 
T1-weighted scan by segmentation. Although MRI is not the preferred imaging modality for 
skull information, the correlation between the MR-estimated and the CT-estimated skull 
thickness results in a correlation coefficient on the order of 0.8 and therefore the calculations 
were performed on the MR images. The skull line was isolated and mapped onto the global 
coordinate system by a custom curve fitting algorithm. The superposition of the axial vector on 
the skull print resulted in their point of intersection I (xI,yI,zI), utilized to obtain the tangent to the 
skull. The tangent vector was estimated as the derivative of the skull curvature at the point of 
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intersection. The incidence 
 
Figure 9: a. 3D representation of the NHP skull obtained from the CT. The transducer in 
solid color is aligned with the skull in a matching curvature regimen while the transparent 
transducers represent cases of not aligned curvatures. Aligned curvatures result in 
sonications with normal incidence angle. b. 3D reconstruction of the BBB opening with the 
focal region of the axial vector (red cylinder), the tangent plane on the skull (green plane) 
and the incidence angle (α) projected. c. Schematic of the skull and definitions of the 
abbreviations used. d. Closer look at the schematic to define the incidence angle. e. Closer 
look at the schematic to define the skull thickness factor, sf, for two different incidence 
angles. f. Closer look at the schematic to define the refraction angle. 
angle was calculated as the angle (α) between the axial vector (𝑉ሬ⃗ ) and the tangent (𝑇ሬ⃗  ) as 
illustrated in Figure 9d based on their dot product.  
𝛼 = 𝑐𝑜𝑠ିଵ 𝑉ሬ⃗ ∗ 𝑇ሬ⃗|𝑉| ∗ |𝑇|     (1) 
The process of incidence angle calculation was repeated for several times per experiment to 
minimize the variance resulting from the tangent vector estimation. The values presented here 
correspond to the mean incidence angle followed by the variance as the error of the 
measurement. The analysis was performed in the 3D domain but the angle of interest is being 
27 
 
formed by the axial direction (z-direction) described by two complementary planes, the z-x and 
the z-y planes. Therefore, the effect of the angle in one of these planes holds for the other as 
well. The coronal plane reported here corresponds to the z-x plane. The projection of the beam 
vector onto the skull yielded the thickness to which the corresponding incidence angle was 
associated. The scaling factor, “sf”, was calculated as the ratio of the skull thickness measured at 
each sonication (di) over the maximum measured thickness (dmax) to scale the factor to unity.  
𝑠𝑓 = 𝑑௜𝑑௠௔௫      (2) 
The targeting accuracy was evaluated by the Euclidian distance of the BBB opening center O 
(xO,yO,zO) from the targeting center F (xF,yF,zF). The magnitude of the geometric shift (𝛥𝑔 =
𝐹𝑂തതതത) is susceptible to the refraction resulting from the variance in the media indices, an estimate 
of which is given by the corresponding angle shift (𝛥𝛼 = |𝛼 −
𝑟|, 𝑤𝑖𝑡ℎ 𝑟 𝑡ℎ𝑒 𝑟𝑒𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑎𝑛𝑔𝑙𝑒). 
 
Finally, the reference scan of each NHP was utilized to construct a five level segmentation map 
of the monkey brain by employing the K-means segmentation method. Overlaying the focal area 
onto the segmentation map revealed the percentage of gray and white matter targeted. 
 
Image processing 
The image processing algorithm resulted in the volume of opening quantification, the targeting 
accuracy estimation and the percentage of opened gray-to-white matter ratio. Precise analysis 
imposed the registration of all T1-weighted images to the reference stereotactically aligned T1-
weighted image using FSL’s FLIRT routine. According to the sequence fundamentals, bright 
areas corresponded to increased contrast agent concentration and distribution including 
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vasculature tracts. It is expected though, that in the T1w-post images enhancement should also be 
observed at the BBB disruption site. For each experiment the T1w-pre image and the 
corresponding T1w-post image were scaled with the muscle intensity to bring the images in 
comparable range. Aiming at the extraction of the VBBB, the ratio of the T1w-post over the T1w-
pre image was obtained, generating the ratio-image. Physiological and magnetic inhomogeneities 
and asymmetric vasculature resulted in unrelated to opening enhancements that were treated with 
filtering. Finally, the BBB opening was defined as the integration of the hyperintense voxels 
exceeding the threshold of 1.1 of the ratio image. The quantification of the distance between the 
focal center and the center of mass yielded the axial and lateral shift of the BBB opening from 
the targeted region. To perform this analysis centroid of the opening was established as the most 
hyperintense voxel in the surrounding spherical region of interest (ROI) (radius=3 mm) of the 
focal center, assuming linearity between the voxel intensity and the tracer concentration. 
 
In silico numerical simulations 
To strengthen the robustness of the in vivo measurements, numerical simulations were employed 
to investigate the incidence angle-effect on the pressure distribution. Therefore, the 3D k-space 
pseudospectral method (k-Wave) was employed to simulate the acoustic wave propagation with 
the second-order wave equation resulting in the transcranial PNP profile under the varying 
incidence angle concept. The acoustic emission source was the single element ring-shaped 
transducer while the sonication parameters (frequency, PRF, duration and duty cycle) were 
identical to the in vivo part of the study106. CT images (helical scan, resolution = 200 × 200 × 
600 μm3; Siemens) were acquired for one of the NHP’s included in this study, providing the 
acoustic properties of the skull (density and speed of sound) converted from the Hounsfield units 
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in CT, with an attenuation of 20dB/cm and the power law absorption exponent of 1.1107. The 
medium properties around the skull were the same as water at body temperature (37⁰C, speed of 
sound = 1524 m/s, density = 1000 kg/m3, attenuation = 3.5×10-4 dB/cm)108. The CT enabled also 
the estimation of the skull thickness for every emission angle, while its segmentation was 
utilized to estimate the incidence angle and compare it to the results obtained from the MRI 
segmentation. 
 
3.1.4 Results and Discussion  
The analysis of 64 sonications resulted in the identification of the correlation between the 
incidence angle of the axial vector and VBBB, the estimation of the geometric shift of the VBBB 
from the target, the skull thickness interference with the incidence angle and finally the VBBB 
overlap with the underlying physiological structures of white- (WM) and gray matter (GM). 
 
The linear increase of the opening volume with incidence angle was confirmed by sonicating at 
three different pressures for five or more times resulting in the three corresponding scatter plots 
illustrated in Figure 10a. The table is summarizing the samples’ number, the fixed pressure and 
the determination coefficient for each plot. It was also confirmed with extensive experiments that 
the variability in opening volume at different pressures resulted from the variability in the 
incidence angle. Therefore, when the incidence angle was fixed at a certain value the linearity 
was restored. Figure 10b demonstrates this effect for three different incidence angles. Finally, the 
reproducibility of our technique was confirmed by repeated sonications with fixed acoustic and 
stereotactic parameters. The results are presented as the mean with the standard error of the mean 




Figure 10: a. Linear regression of the opening volume with increasing incidence angle at 
three different pressures. The variables are listed in the table preceding the graphs. b. 
Linear regression of the opening volume with increasing pressure at three different 
incidence angles. The variables are listed in the table preceding the graphs. c. Repeatability 
of the opening volume at fixed pressure sand incidence angles. The variables are listed in 
the table preceding the graphs. 
Pairwise observations provide further insight into the correlations. The most interesting finding 
in this study was the strong dependence of the VBBB on the incidence angle of the propagating 
wave. Figures 10 and 11 show that at a fixed PNP, a strong correlation exists between the 
incidence angle and the VBBB. The pressure applied was kept constant and the angle against the 
opening size was plotted to demonstrate that the opening increases with incidence angle, 
confirming the hypothesis that a normal angle is preferred for larger openings. This is true due to 
the shorter propagation path through the skull after alignment of the transducer curvature to the 
skull lines and thus lower susceptibility to attenuation effects. By maintaining the incidence 
angle fixed and increasing the PNP, the BBB opening volume was steadily increased confirming 
previous findings in rodents. This observation was confirmed by both qualitative and quantitative 
findings. Ultimately, by varying both the PNP and angle the BBB opening volume can be altered 
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accordingly to achieve the desired treatment by simultaneously protecting the neighboring 
regions. On the other hand, by keeping both parameters fixed over the course of treatments the 
same opening can be reproduced (Figures 10c and 11c). This indicates a priori planning of the 
incidence angle and the applied pressure for each subject separately.  
 
Figure 11: a. Qualitative results showing increase of the volume of opening with incidence 
angle for fixed pressure, 0.4MPa. The NHP in the blue outline was sonicated at 73±1.5° 
yielding an opening of 142±20 mm3 while the NHP in the red outline yielded an opening of 
481±30 mm3 when sonicated at 88±1.2°. b. Brain images showing the increase of the volume 
of opening with pressure given a constant incidence angle, 76±1.5°. The NHP in the blue 
outline was sonicated at 0.35 MPa and yielded an opening of 246±22 mm3 while the NHP in 
the red outline was sonicated at 0.6MPa yielding an opening of 854±50 mm3. c. Qualitative 
results showing the repeatability of the technique. Both NHPs were sonicated at 




These findings were confirmed in silico by numerical simulations showing that increase of the 
incidence angle resulted in a more uniform PNP profile shifted towards higher pressures (Figure 
12). Manipulation of the incidence angle and the pressure is of immense importance since 
various configurations of angle and pressure could be achieved. In the case of clinical trials, 
angle variation is valuable in avoiding specific structures while lower pressures will be applied. 
Furthermore, numerical simulations were comparable to the in vivo results in the context of 
incidence angle estimation and skull thickness effect. 
 
Figure 12: Numerical simulations with increasing incidence angle and constant pressure at 
0.3 MPa, Axial and lateral profile for the five angles respectively, 78.46, 80.784, 82.21, 86.19 
and 88.02. The PNP field was normalized with the maximum pressure across simulations. 
Another interesting observation is the non-uniform shape of the opening site in several cases, 
some of which are presented in Figure 11. This observation suggested a more thorough 
investigation of the underlying physiology that could affect the BBB opening volume 
distribution. Therefore, measurements of the gray-to-white matter ratio at the targeted and the 
opened site showed that regardless of the targeting trajectory, the opening percentage on gray 
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matter is in the range of 75-90% while the white matter occupies only 10-25% of the opening 
site. This finding was observed in all NHPs and was found invariant of the ultrasound 
parameters. Regional differences in vascularization and subsequent microbubble concentration 
play a significant role in the probability of inducing an opening. It has been established that gray 
matter is highly dense in capillaries unlike white matter while variation even within gray matter 
depends on the structure’s metabolic demand and synaptic needs109,110.  
 
The targeting accuracy was estimated by the axial shift on the order of 2.36±1.74 mm towards 
the direction of the transducer and the lateral shift on the order of 1.18±1.05 mm to the lateral 
direction when targeting the Putamen region. For the Caudate nucleus the displacements were 
1.58±1.02 mm towards the direction of the transducer and 1.05±0.37 mm to the lateral direction. 
The errors correspond to the standard deviations. Apart from the geometric displacement of the 
opening, its orientation is of equal importance whereas the divergence of the refraction angle 
from the incidence angle was 4.5±3° when targeting the Putamen region and 3.65±1.3° at the 
Caudate nucleus. Finally, T2-weighted and SWI imaging confirmed the safety of the repeated 
sonications under the selected sonication regime.  
 
3.1.5 Limitations and Conclusions 
As described in the methods’ section, the angle estimation was based on the superposition of the 
stereotactic geometry on the skull line and therefore the angle calculation could be considered 
indirect. This indirect method is susceptible to errors resulting from image artifacts, skull 
extraction algorithm or tangent plane estimation. Averaging eliminates these analysis’ errors but 




Furthermore, erroneous positioning of the manipulator and the drivers could result in divergence 
from the desired and designed focus resulting to misleading interpretations of the results on 
geometric shift. Further investigation in the white and gray mater diffusion mechanisms is 
necessary and is pointing towards the direction of diffusion- and perfusion-based MRI 
techniques. 
 
Further investigation of the diffusion components affecting the physiology of the targeted 
structures should give more insight into the mechanisms involved in BBB opening. 
 
In this aim, the dependence of the BBB opening volume on the incidence angle, the effect of the 
gray-to-white matter ratio on the BBB opening shape and the targeting accuracy were 
established. It was found that the BBB opening volume increased monotonically with both the 
incidence angle and PNP. Pairwise observations revealed the linearity between the VBBB and the 
incidence angle at the same pressure and interchangeably the monotonic increase of the VBBB 
with PNP at the same angle. As expected, the VBBB induced by the same incidence angle and 
PNP over the course of several sonications at different days resulted in comparable results. These 
findings indicate that the BBB opening volume can be predicted and planned by the selection of 
the corresponding combination of incidence angle and PNP. Additionally, the opening was found 
to be five times more pronounced in the gray matter than in the white matter indicating the effect 
of gray-to-white matter ratio on the BBB opened region. Finally, the technique was proven 
accurate and safe, given the shifts were deemed acceptable and the corresponding safety scans 




3.2 Contrast-free detection of the focused ultrasound-induced blood-brain barrier opening 
with magnetic resonance imaging in non-human primates, in vivo. 
3.2.1 Abstract 
FUS has emerged as a non-invasive technique to locally and reversibly disrupt the blood-brain 
barrier (BBB). Here, we investigate the use of diffusion tensor imaging (DTI) as a means of 
detecting FUS-induced BBB opening at the absence of an MRI contrast agent. A non-human 
primate was treated with FUS and preformed circulating microbubbles to transiently disrupt the 
BBB (n = 4). T1- and diffusion-weighted MRI scans were acquired after the ultrasound 
treatment, with and without gadolinium-based contrast agent, respectively. Both scans were 
registered with a high-resolution T1-weighted scan of the NHP to investigate signal correlations. 
DTI detected an increase in the fractional anisotropy from 0.21 ± 0.02 to 0.38 ± 0.03 (82.6 ± 5.2 
% change) within the targeted area one hour after BBB opening. Enhanced DTI contrast 
correlated with hyper-intense areas of gadolinium-enhanced T1-weighted scans, indicating 
diffusion enhancement only within the BBB opening area. Diffusion enhancement was highly 
anisotropic and unidirectional within the treated brain region, as indicated by the direction of the 
principal diffusion eigenvectors. Polar and azimuthal angle ranges decreased by 35.6% and 
82.4%, respectively, following BBB opening. In conclusion, DTI may be used as a contrast-free 
MR imaging modality in place of contrast-enhanced T1 mapping for detecting BBB opening 




3.2.2 Introduction  
Brain tumors and neurodegenerative diseases remain undertreated largely due to the presence of 
the BBB. FUS in conjunction with pre-formed microbubbles has been studied for more than 15 
years as a means to facilitate the delivery of a wide range of therapeutic agents76,111–115 through 
the BBB. Following a large body of promising pre-clinical work, a number of clinical trials are 
currently in progress, aiming to efficiently and safely open the BBB in patients with Alzheimer’s 
disease116, glioblastoma117 and amyotrophic lateral sclerosis118. The gold standard for the 
detection of FUS-induced BBB opening is contrast-enhanced T1-weighted MRI64,101,116,117,119. 
Gd-based contrast agents (GBCAs) typically have a molecular weight of approximately 600 Da 
and are naturally impermeable to the intact BBB. Given their size, GBCAs can delineate even 
moderate BBB opening and also provide spatiotemporal information of vascular permeability 
variation via dynamic contrast-enhanced (DCE) MRI48,101,120,121. 
 
Although GBCAs have an established safety profile, there are raising concerns regarding their 
toxicity and tissue retention. Linear GBCAs have been occasionally correlated with 
hypersensitivity reactions and nephrogenic systemic fibrosis122,123. There has been evidence that 
Gd is retained within certain areas of the brain (e.g., the dentate nucleus) following repeated 
administration of linear GBCAs124–127, an effect which is exacerbated in subjects with renal 
impairment128,129 and in pediatric patients130,131. Regulatory authorities have therefore 
recommended the gradual replacement of linear GBCAs with macrocyclic GBCAs that have a 
lower retention rate and limited deposition into the brain132,133. However, the long-term effects of 




The growing safety concerns over GBCAs surfaced the necessity to explore non-Gd alternatives. 
The carboxymethyldextran coated-iron oxide nanoparticle, Ferumoxytol, has been investigated 
as a potential candidate134. However, lacking the molecular characteristics and pharmacokinetic 
properties of GBCAs, it provided only complementary information and was deemed unsuitable 
for BBB disruption detection134. To overcome the shortfalls of iron oxide nanoparticles, 
complexes of manganese-based contrast agents were developed135,136. Manganese is a trace 
element, essential for physiological body functions, with strong paramagnetic properties 
inducing increased relaxation135,136. However, engineering effective and stable manganese-based 
contrast agents has been proven challenging but promising following the development of the 
Mn-PyC3A compound135. Additionally, arterial spin labeling has been also introduced as a 
substitute to contrast-enhanced imaging techniques, primarily focusing on the quantitative 
measurement of tissue perfusion137. Despite the alternatives, further investigation is needed to 
completely replace contrast-enhanced MRI with contrast-free MRI as the gold standard for 
evaluating spatial variations in BBB integrity and FUS-induced BBB opening in particular. 
 
Herein, we explore and evaluate the potential of diffusion-weighted imaging (DWI) as a 
promising candidate for replacing contrast-enhanced T1-weighted imaging in detecting BBB 
permeability. DWI has been extensively used in brain applications including the diagnosis of 
stroke138–140, edema formation141, subarachnoid hemorrhage142 and multiple sclerosis143,144. In 
this context, diffusion refers to the random translational motion of molecules (i.e., Brownian 
motion) driven by the thermal energy carried by the molecules145,146. During displacement, 
molecules probe the surrounding tissue at a microscopic scale. The resulting displacement 
distribution, reflecting differences in tissue organization, is captured in the DWI image 
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contrast147. The capabilities of this technique expand further to the detection of the displacement 
directionality (isotropic or anisotropic) associated with gradient pulses driven at different 
directions sensitizing displacements along that direction146, namely the diffusion tensor imaging 
(DTI)146,148. In DTI, diffusion-weighted images are acquired along multiple directions (i.e. at 
least 6 directions) along with an image acquired without weighting (b = 0 s/mm2) in order to 
populate the diffusion tensor, which is a three-by-three, symmetric, positive definite matrix148. 
Diffusion tensor D is connected with the diffusion-weighted signal intensity Sk and the b = 0 
s/mm2 signal S0 via the Stejskal and Tanner equation149,150: 
𝑆௞ = 𝑆଴𝑒ି௚ොೖ௕௚ොೖ೅𝑫    , 𝑤𝑖𝑡ℎ 𝑏 = 𝛾ଶ𝐺ଶ𝛿ଶ ൬𝛥 − 
𝛿
3൰   (3) 
 
where g ̂_k is the kth gradient direction, γ is the gyromagnetic ratio, G is the amplitude of the 
diffusion gradients, δ is the diffusion gradient duration, and Δ is the interval between two 
successive diffusion gradients on either side of the refocusing pulse149. The eigenvectors (v1, v2, 
v3) and eigenvalues (λ1, λ2, λ3 with λ1 ≥ λ2 ≥ λ3) of the diffusion tensor D can be computed to 
characterize the diffusion ellipsoid in each voxel. Spherical ellipsoids (λ1 ≈ λ2 ≈ λ3) indicate 
symmetric and isotropic water diffusion, while planar (λ1 ≈ λ2 > λ3) and tubular (λ1 > λ2 ≈ λ3) 
ellipsoids indicate asymmetric and anisotropic water diffusion. Anisotropic water diffusion is 
routinely employed to identify white matter tracts at high resolution, in MR tractography 
applications150–152. A frequently used metric of diffusion anisotropy in the interval [0,1] is 
fractional anisotropy (FA), a non-linear combination of the eigenvalues defined as153,154: 
𝐹𝐴 =  ඨ32
(𝜆ଵ − 𝜆ଶ)ଶ + (𝜆ଵ − 𝜆ଷ)ଶ + (𝜆ଶ − 𝜆ଷ)ଶ
𝜆ଵଶ + 𝜆ଶଶ + 𝜆ଷଶ




FA maps have been previously used to identify the causes of epilepsy155, schizophrenia156, 
amyotrophic lateral sclerosis157, and dyslexia158. Additionally, FA mapping can identify 
morphological changes in axons following traumatic brain injury159. Interestingly, FA values 
change following repeated BBB disruption induced by traumatic brain injury in football 
players160. In the context of FUS-mediated BBB opening, DTI revealed normal microstructure 
and tissue integrity in repeatedly treated rodents over a period of months161. 
 
In this study, we hypothesized that a localized FUS-induced BBB opening will induce a change 
in the diffusion ellipsoids within the targeted area. The direction of the principal diffusion vector 
v1 and the FA values were both expected to locally change after FUS treatment due to the 
anisotropic stresses exerted by asymmetric microbubble oscillations within the 
microvasculature162. This hypothesis was investigated in a NHP model, which closely resembles 
the human brain and skull. The correlation between the contrast-enhanced T1-weighted and DTI 
was examined in terms of accurately detecting and quantifying the FUS-induced BBB opening. 
The overall aim is to provide an alternative to the potentially toxic GBCA systemic injection 
required for T1-weighted MRI with a Gd-free MR sequence. 
 
3.2.3 Materials and Methods  
In vivo experiments 
The experimental procedure was similar to the one described previously (section 3.1.4). Briefly a 
male rhesus macaques (Macaca mulatta) was employed for this study while at least two weeks 
were interleaved between sessions. During each procedure, the animal was immobilized by 
intramuscular administration of a cocktail containing 1ml ketamine (5-15 mg/kg) and 1ml 
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atropine (5-15 mg/kg), while in the operation room, the animals were anesthetized by inhalation 
of 1–3% isoflurane. The transducer was attached to the Kopf stereotaxic manipulator to allow for 
targeting the brain in the stereotaxic coordinate frame and the animals were transferred to the 
MRI site immediately after the sonication (Figure 13a). 
 
Focused ultrasound  
Similar to the previous section (section 3.1.3), the sonications were carried out by a single-
element, spherical-segment FUS transducer operating at 0.5 MHz with a flatband, spherically 
focused hydrophone confocally alligned at the central void of the transducer. In-house 
manufactured, lipid-shell, monodisperse microbubbles with a mean diameter of 4 to 5 μm were 
diluted to 2×105 # bubbles/mL. The microbubbles at a dosage of 2.5×108 # bubbles/kg were 
intravenously injected through the saphenous vein 10 sec after the onset of sonication to allow 
for real-time monitoring of the microbubble cavitation described elsewhere. The animals were 
sonicated in the Caudate nucleus for 120 sec, at an incidence angle of 85 ± 2˚, pulse length pulse 
repetition frequency of 2 Hz, pulse length of 10 ms and PNP at 0.45 MPa. 
 
The targeting optimization performed previously (section 3.1.4) resulted in the selection of 
optimal stereotactic parameters with a normal incidence angle. This parametric space was 
utilized in this aim to achieve the largest opening volume in the Caudate nucleus under the safety 
regime while was kept constant to ensure repeatability. Evaluation of the targeting accuracy was 
performed by implementation of the stereotactic device’s geometric characteristics into the 
MATLAB algorithm described previously (section 3.1.4) resulting into the overlay of the focal 


















































































































Contrast-enhanced T1-weighted imaging protocol 
Following the FUS procedure, the animal was transferred to the MRI scanner (3T Philips 
Achieva) for contrast-free DTI and contrast-enhanced T1-weighted imaging. As previously 
described119 high-resolution structural contrast-enhanced T1-weighted images were acquired 
(Gradient Echo, TR/TE= 11.16 ms /5.14 ms, flip angle= 8º, FOV= 120 x 120 mm2, matrix size: 
176 x 176, NSA=1, slice thickness 0.7 mm, 171 slices) at two time-points. The pre-sonication 
scan (T1PRE) was acquired 30 minutes after intravenous administration of 0.2 ml/kg GBCA 
(gadodiamide) preceding any sonication while the post-sonication scan (T1POST) was acquired 
after every sonication. T1-weighted imaging was employed as the gold standard in BBB opening 
detection to compare with the new imaging modality. DTI always preceded any contrast 
injection to avoid signal distortion due to the Gd presence.  
 
DTI protocol and analysis 
DTI sequence 
The DTI protocol consisted of a multi-shot spin-echo echo planar DTI sequence with TR/TE= 
3475/72 ms/ms, flip angle= 90º, FOV= 120 × 120 mm2, matrix size: 128 × 128, NSA= 1, slice 
thickness 2 mm, 28 slices, 15 different weighted gradient directions and a b-value equal to 700 
s/mm2. An accelerated DTI scan with SENSE (Sensitivity encoding) factor 2 was acquired (scan 
time < 10 min) prior to the initiation of the experiments (DTIPRE) and one immediately after 
every sonication (DTIPOST) to enable intra-brain comparison of the diffusion metrics before and 
after the BBB opening. 
 
DTI registration with ANTS library 
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The raw data collected from the MRI scanner were converted from a digital imaging and 
communications in medicine (DICOM) format to a neuroimaging informatics technology 
initiative (NIFTI) format prior to the analysis (Figure 13c). The susceptibility of this technique to 
various artifacts and the necessity of single pixel precision dictated the need for a sophisticated 
registration algorithm. The Advanced Normalization Tools (ANTS) library was employed to 
register all directions of the DTI scans (DTIPRE  and DTIPOST ) to the reference scan, which in 
this case was the diffusion gradient-free (b = 0 s/mm2), weight-free direction of the DTIPRE scan, 
𝑆଴௉ோா (Figure 13c). ANTs is a software package, built on an Insight Toolkit framework, 
comprised of powerful tools for image registration and segmentation163 that belongs to the 
highest-ranking registration methods164. The default executable “antsRegistrationSyN” that was 
implemented, performs a symmetric, geodesic diffeomorphic transformation. It follows the 
principles of an extended Lagrangian diffeomorphic technique165, that based on a time-varying 
velocity field optimization results in the alignment of two images. Symmetric mapping 
guarantees that the path from the “moving” image to the “reference” image is the same as the 
path from the “reference” to the “moving” image regardless of the similarity metric and the 
optimization parameters165. In this deformation space, the shortest paths between elements are 
termed geodesic while diffeomorphism refers to a differentiable map with a differentiable 
inverse165 
 
The registration was initialized with rigid and affine mapping (Figure 13c) to linearly transform 
the “moving” image to the orientation of the “reference” image. Linear transformation is 
necessary to meet the symmetric diffeomorphisms’ assumption of homogeneous boundary 
conditions (image borders map to themselves) for solutions restricted to the diffeomorphic 
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space165. Hence, ANTs assumes that a diffeomorphism “φ” defined on the image domain “Ω” 
maintains an affine transform at the boundaries. Over time, the map “φ” parametrizes a group of 
diffeomorphisms by integrating a time-dependent, smooth velocity field described largely 
by163,165: 




ቋ , 𝑤𝑖𝑡ℎ       (5) 




𝜆 න ෑ (𝐼, 𝜑(𝑥, 1), 𝐽)𝑑𝛺
~
 𝑡ℎ𝑒 𝑠𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦 𝑚𝑒𝑡𝑟𝑖𝑐       (7) 
where u denotes the velocity, L the smoothing operator, t the time, λ controls the matching 
exactness, x is the spatial position, Π~ is the similarity metric and I is the moving image to be 
transformed to the reference image J.  In the registration schema employed herein, geodesic 
transformation with Gaussian regularization was the transformation model of choice along with 
the Mutual Information metric as the similarity measure and Gradient Descent accounting as the 
optimization method163. 
 
Following the registration, all directions per scan were organized into a 4D matrix (one 3D 
image per gradient) that along with the corresponding gradient directions and the weighting 
factors was used by FSL’s FDT Diffusion platform as input166. Prior to further processing, the 
brain tissue was isolated from the skull and the muscle by employing FSL’s Brain Extraction 
Tool (BET) with the default fractional intensity threshold, 0.5167. Eddy current correction 
followed the brain masking by simulating the diffusion signal using a Gaussian Process 
assuming that: i) the signal from two acquisitions acquired with diffusion weighting along two 
vectors with a small angle between them is more similar than for two acquisitions with a large 
angle between them and, ii) the signal from two acquisitions along vectors v and -v is identical. 
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The diffusion encoding directions have been chosen to span the entire sphere (Figure 13b) 
facilitating the distinction between signal variation caused by diffusion and that caused by eddy 
currents/movements168.  Finally, estimation of the tensor matrix was accomplished by utilizing 
FSL’s DTIFIT command resulting in the calculation of the associated eigenvectors/eigenvalues 
(V1, V2, V3, L1, L2 and L3) and the corresponding maps.  
 
Upon the local directionality of the water diffusion, every structure has a distinct FA value, while 
a change in that value was hypothesized to occur after BBB opening. To detect the change in the 
local diffusivity pattern, the difference in the FA maps was calculated, ΔFA= FAPOST- FAPRE. 
The resulting maps were smoothed using a two-dimensional median finite impulse response filter 
(2 x 1 pixels), in order to eliminate the noisy background. To visualize the local changes and 
their correlation to the BBB opening and the underlying anatomy, the ΔFA images were 
superimposed onto the anatomical images and the BBB opening. These T1-weighted high-
resolution anatomical images were registered to the diffusion reference scan in MATLAB using 
a multimodal, three-dimensional, intensity-based, affine registration. This approach provided 
acceptable overlap between structures observed in T1 and DTI images, therefore more advanced 
registration was not attempted. 
 
Quantification 
Quantification of the BBB opening was performed in MATLAB for both imaging sequences. To 
detect the BBB opening, the ratio RGd-T1 = Gd-T1POST / Gd-T1PRE was calculated following 
reference-intensity scaling between each T1PRE and T1POST pair119. The within-plane surface area 
of the BBB opening was calculated as the sum of the pixels with intensity surpassing the 
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threshold of 1.1. A similar approach was followed for the FA maps by calculating the ΔFA 
difference following reference-intensity normalization. Integration of the pixels surpassing zero 
resulted in the estimation of the within-plane BBB opening area. Although the entire volume of 
the BBB opening could be estimated from the anatomical images, that was not the case for the 
DTI. To minimize the acquisition time while increasing the number of gradient directions during 
DWI acquisition, the number of slices was decreased resulting in the observation of the BBB 
opening in primarily a single plane. Therefore, for consistency and comparability of the BBB 
opening between the two modalities, the BBB surface area is being compared between the FA 
and the gold standard. 
 
To assess any changes in the diffusion pattern following BBB opening, the average FA value 
within the BBB opening area has been quantified. To report on the directionality of the 
molecules, the polar and azimuthal angles of the primary eigenvectors have been summarized in 
polar plots with an angle bin of 5˚. Finally, the polar and azimuthal angle ranges have been 
quantified for both ipsilateral and contralateral hemisphere, used here as the control. 
 
Statistical analysis 
Data shown here are presented as mean ± standard deviation (n = 4 FUS treatments). 
Comparisons between FAPRE and FAPOST values and angle ranges were analyzed using a two-
tailed paired Student’s t-test while comparison of the BBB opening size between modalities was 
conducted with two-tailed unpaired Student’s t-test.  In all analyses, the null hypothesis was 
rejected at the 0.05 level. All statistical analyses were performed using Prism 8 (GraphPad 
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ultrasound (t[3]=27.73; P=0.0001). The increase of FA was reversible, e.g. the region with 
opened BBB in the first FUS treatment was not enhanced in subsequent scans. This suggests that 
the detected FA increase is due to the reversible BBB opening and not to a permanent change 
within the gray matter, such as persisting edema or scar tissue.  
 
The local change in diffusivity that co-localizes with the BBB opening was found to follow a 
preferred direction, hence the positive change in the FA value. This finding was confirmed by 
the vector field that depicts the vectors of the voxels corresponding to the BBB opening pointing 
towards one direction, with a high degree of anisotropy. In Figure 15, the BBB opening is 
overlaid on the primary vector field (v1) and the magnified part of the brain shows the 
directionality of the vectors in the ipsilateral and contralateral caudate. Moreover, the primary 
diffusion eigenvectors (v1) had consistent polar and azimuthal angles within the disrupted 
ipsilateral region (v1POST-IPSI), in contrast to the same region prior to the opening (v1PRE-IPSI) as 
well as the contralateral region (v1POST-CONTRA), where in both latter cases the v1 experienced a 
more isotropic and uniform angle distribution as shown by the angle plots in Figure 15. 
Quantification of the polar and azimuthal angles spanning range was estimated as the difference 
in the most distant angles (polar and azimuthal) for the three cases (v1POST-IPSI, v1PRE-IPSI, v1POST-
CONTRA) revealing a significantly narrower range only in the BBB opening cases. Cumulative 
results showed a decrease in the polar angle range of the v1POST-IPSI on the order of 35.58% 
(t[3]=3.921; P=0.0295) compared to the pre-sonication scan, v1PRE-IPSI, and 53.86% (t[3]=4.887; 
P=0.0164) compared to the post-sonication contralateral side, v1POST-CONTRA. Similarly, the 
azimuthal angle range of the v1POST-IPSI decreased by 82.44% (t[3]=3.699; P=0.0343) compared 
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area shows comparability of the two modalities both qualitatively and quantitatively. 
Accordingly, the average BBB opening surface area is similar between modalities. The FA 
value increased in all four cases following the sonication while increased on average by 
82% from 0.21 ± 0.02 to 0.38 ± 0.03 (t[3]=27.73; P=0.0001).     
The individual values of the BBB opening surface area, FAPRE, FAPOST, ΔFA as well as the polar 
and azimuthal angle ranges for v1POST-IPSI, v1PRE-IPSI, v1POST-CONTRA are summarized in Table I. 
 
Diffusion weighted images processed with non-linear registration and tensor analysis revealed 
the sites of BBB leakage that correlated well with the BBB-opened regions detected by Gd-T1-
weighted imaging (Figure 14). Moreover, the FA maps showed an increase in the anisotropy in 
the area of BBB opening indicated by a positive increase in the FA amplitude, also confirmed by 
vector analysis and the respective angles (Figure 15). Mean diffusivity maps were also computed 
but no significant change was observed following the sonications. Based on prior findings, this 
observation could be attributed to the equivalence of averaging similar eigenvalues (λ1≈ λ2≈ λ3) 
to averaging eigenvalues whereas the primary is distantly large compared to the remaining two 
(λ1 ≫ λ2≈ λ3) (see mean diffusivity equation, Figure 13c). 
 
The highly anisotropic nature of v1 within the targeted area (Figure 15) was the underlying cause 
to the increased FA value. We hypothesize that increased anisotropy stems from the non-uniform 
stresses exerted by the oscillating microbubbles in the vicinity of cerebral blood vessels162,169.  
Sonication at pulse lengths on the order of milliseconds can promote primary acoustic radiation 
forces170,171, microbubble cluster formation172–174, and microbubble coalescence175, thus 
producing inhomogeneous stimuli and non-uniform BBB opening87. Therapeutic FUS exposure 
forces microbubbles to move in the direction of ultrasound propagation at velocities on the order 
 of m/s, which is expected to lead in BBB op
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Figure 15: DTI eigenvectors overlaid onto the ΔFA map for the entire axial brain plane and 
the magnified striatal region. BBB opening initiates an increase in the directionality of the 
water molecule diffusion compared to the intact barrier shown by the consistent direction 
of the arrows in the sonicated area compared to the contralateral side. Polar and azimuthal 
angle distributions in the ipsilateral and contralateral hemispheres are presented showing 
the narrow range of polar and azimuthal angles of the principal eigenvector only at the site 
of sonication (v1POST-IPSI). Cumulative results showed a decrease in the polar angle range on 
the order of 35.58% (t[3]=3.921; P=0.0295) compared to the ipsilateral side, v1PRE-IPSI, and 
53.86% (t[3]=4.887; P=0.0164) compared to the contralateral side, v1POST-CONTRA. Similarly, 
the azimuthal angle range of the v1POST-IPSI decreased by 82.44% (t[3]=3.699; P=0.0343) 
compared to v1PRE-IPSI, and 84.55% (t[3]=7.462; P=0.005) compared v1POST-CONTRA. 
FUS transducer176,177. This hypothesis is supported by the similar directionality observed in both 
polar and azimuthal angles in all BBB openings (Figure 15). Another potential effect following 
BBB opening is a change in the CSF circulation pattern178,179. Pressure gradients may 
temporarily affect the local CSF flow, leading to increased water diffusion anisotropy. Our 
sequences were able to detect the bulk FA increase, but other sequences such as phase-based 
amplified MRI180,181 may be needed to resolve sub-voxel CSF motion patterns. Another similar 
study conducted in rodents confirmed the increase in FA values following repeated sonications 
although using a different timeline. In that study the increased directionality was attributed to 
increased myelin integrity161.  
 
3.2.5 Limitations and Conclusions  
Regardless of the underpinning mechanism, the increase of FA is temporary and is restored upon 
BBB closing. Future work will investigate the temporal evolution of FA maps following BBB 
opening. Numerical modeling of interstitial pressure gradients and CSF flow following BBB 
opening may elucidate the mechanism driving the anisotropic water diffusion. We will compare 
ms-long pulse sequences against μs-long pulse sequences, which were shown to produce more 
homogeneous microbubble activity in vitro174 and more uniform BBB opening in vivo87,182. We 
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anticipate that the diffusion anisotropy will be less pronounced following FUS treatment with μs-
long pulses. We also aim to correlate the BBB opening volume derived through DTI with passive 
cavitation mapping of microbubble activity within the NHP brain44,45,183,184. Finally, the DTI 
quality can be further improved by adjusting the gradient tables and eliminating potential 
imaging artifacts due to subject motion185. 
 
In conclusion, in this aim a non-contrast MR-based imaging approach for BBB opening was 
described. The FA maps were shown to vary as a result of FUS-mediated BBB opening, and that 
change co-localizes with the GBCA extravasation area in contrast-enhanced, T1-weighted MRI. 
Therefore, DTI is concluded to constitute a reliable contrast-free alternative, which may be 
proven safer by avoiding MRI contrast to permeate into the brain parenchyma. DTI may be used 




It has previously been shown by numerical simulations that incidence angles deviating from 
normal lead to strong wave reflections and extremely high attenuations caused by the primate 
skull curvature102. However, the correlation of the incidence angle -corrected by the skull 
thickness- with the BBB opening volume was quantified and analyzed here for the first time, 
combining numerical simulations and in vivo experimentation. Regional differences in 
vascularization and subsequent microbubble concentration defined the probability of inducing a 




Sonications with optimized parameters (normal-to-the-skull-curvature incidence angle, pressure 
level, thin skull area) in a single NHP yield highly repeatable BBB openings detectable by DTI. 
For the first time, we proved that Gd-T1-weighted imaging can be substituted by contrast free 
imaging but more importantly, we established the anisotropic diffusion pattern following the 
BBB opening.  
 
The overall contribution of this study is the identification of the parametric space of ultrasonic 
trajectories resulting in predictable BBB opening volumes for varying pressure levels. The 
expectation of inducing a BBB opening is five times higher in GM regions compared to WM 
matter hence the higher vascularization density. DTI employed as the BBB opening detection 
schema reveals the anisotropic nature of diffusion. The findings of these studies have been 
accounted for in the upcoming clinical trial restricting incidence angles to normal and selecting 
DTI as the detection sequence186. The results of the studies described in this chapter have been 
published in peer reviewed scientific journals119 (Figure 16). 
 
Regarding the research contribution, Professor Vincent P. Ferrera, Ph.D. (Associate Professor, 
Neuroscience, Psychiatry, Columbia University) provided assistance with the animal subjects 
along with his scientific input. Matthew Downs, Ph.D. (Postdoctoral Research Scientist, 
Biomedical Engineering, Columbia University) assisted with the animal preparation and the 
sonications while Gesthimani Samiotaki, Ph.D. (Postdoctoral Research Scientist, Biomedical 
Engineering, Columbia University) assisted with MRI optimization and data processing.  
Antonios N. Pouliopoulos, Ph.D. (Associate Research Scientist, Biomedical Engineering, 
Columbia University) worked on the data processing part of the study optimizing the registration 
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and filtering techniques while Michael Liu, M.S. (Ph.D. student, Radiology, Columbia 
University) provided great insight and suggestions in the non-linear registration validation and 
evaluation of the results. Most importantly, the author would like to thank Dr. Sachin 
Jambawalikar (Assistant Professor of Radiology – Physics, Columbia University) for assisting 
with the optimization of MRI scanning sequences, data handling, data analysis, mathematical 
















Chapter 4: Focused ultrasound-facilitated neurotrophic delivery in 
an early-stage Parkinsonian mouse model. 
Establishing in Chapter 3 the normal incidence angle as a predicting factor of the BBB opening 
volume in the striatum (Caudate nucleus) defined the sonication regime employed herein for 
transgenic animal models with profound neurodegeneration at the striatal region, among others. 
The next specific aim and milestone entails the use of the FUS method for neurotrophic factor 
delivery in the striatum and midbrain of the subacute MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) mouse model, mimicking early stage PD19. 
 
4.1 Abstract 
The BBB prevents most drugs from gaining access to the brain parenchyma, which is a 
recognized impediment to the treatment of neurodegenerative disorders like Parkinson’s disease.  
FUS, in conjunction with systemically administered microbubbles, opens the BBB locally, 
reversibly and non-invasively.  Herein, we show that neither FUS applied over both the striatum 
and the ventral midbrain, without neurotrophic factors, nor intravenous administration of 
neurotrophic factors (either through protein or gene delivery) without FUS, ameliorates the 
damage to the nigrostriatal dopaminergic pathway in the sub-acute MPTP mouse model of early-
stage PD (Figure 17). Conversely, the combination of FUS and intravenous neurotrophic (protein 
or gene) delivery attenuates the damage to the nigrostriatal dopaminergic pathway, by allowing 
the entry of these agents into the brain parenchyma. Our findings provide evidence that the 
application of FUS at the early stages of PD facilitates critical neurotrophic delivery that can 
curb the rapid progression of neurodegeneration while improving the neuronal function, 
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seemingly opening new therapeutic avenues for the early treatment of diseases of the central 
nervous system. 
 
Figure 16: Upregulation of the dopaminergic pathway following focused ultrasound-
facilitated drug delivery. The dopaminergic pathway can be downregulated similar to 
Parkinson’s disease in toxin-based mouse models. Application of focused ultrasound results 
in increased blood-brain barrier permeability allowing the diffusion of pharmacological 
agents in the brain. Depending on the number of administrations and the delivery vehicle, 
the deliverable compounds can have beneficial effects of varying degree. 
 
4.2 Introduction 
The BBB poses a hindrance to the treatment of adult-onset neurodegenerative disorders, like PD, 
preventing most drugs from gaining access to the brain parenchyma. Among the existing drug 
delivery techniques25 aiming to overcome the BBB, FUS coupled with the administration of 
microbubbles prevails hence its efficacy profile –non-invasive, targeted, transient. 
 
FUS has been shown to produce a safe disruption of the BBB in various animal species and in 
experimental models of human diseases. The initiated biological effects are confined to the 
vessel walls only and contained solely within the targeted region26. Within a certain parametric 
range, the integrity of the BBB can be restored within hours and remain intact94. Single 
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administration of therapeutic agents alleviating the associated disease symptoms have been 
proven successful while  FUS-mediated gene delivery advantages overcome conventional 
techniques147,187,188. 
 
The adherence of this chapter on trophic factors in PD stems from the large body of literature 
showing that neurotrophic factors such as GDNF and NTN can impede the degeneration of the 
dopaminergic (DA) neurons in the substantia nigra pars compacta, and to restore the function of 
the injured DA neurons in experimental models of PD189–191. Furthermore, both GDNF and NTN 
have been tested in humans. Intraputamenal infusion of GDNF resulted in functional 
improvement in 15 advanced PD patients as reported by two Phase I clinical trials, while the 
25% amelioration in motor scores was not achieved in 17 out of the 34 PD patients in a phase II 
clinical trial. Likewise, intrastriatal delivery of the Adeno-associated type 2 viral vector encoding 
human NTN (AAV2-NTN) showed preventive effects on MPTP-induced motor disability in 
non-human primates, but clinical trials failed to show significant disease-modifying effects192. 
Despite the negative results of these Phase II studies, which might be due to technical issues193–
195, both GDNF and NTN remain quite appealing molecules for the present work given their 
well-established effects on the DA pathways196,197. 
 
We have previously reported that FUS enhances the delivery of NTN in wild-type mice, non-
invasively and locally at the level of PD-relevant brain regions112. Briefly, the area of NTN 
bioavailability, under the same ultrasound parameters as herein, was 5.07 ± 0.64 mm2 in the 
striatum (designated thereafter caudate-putamen [CPu]) and 2.25 ± 1.14 mm2 in the midbrain, 
showing the presence of NTN across the entire ultrasound-treated brain region compared to the 
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relatively smaller region reached by direct injection.  In this previous work, we also demonstrate 
that NTN cannot only be delivered successfully to the ventral midbrain through the FUS-induced 
reversible BBB-opening112, but also that the permeate NTN retains its bioactivity as evidenced 
by the local activation of the downstream signaling pathway.  This finding is particularly 
significant since the nigrostriatal pathway, which connects the ventral midbrain region with the 
CPu, is the most severely-affected DA pathway in PD19. 
 
The response of early stage PD patients to DA stimulation22 raises the question as to whether the 
targeting of the nigrostriatal pathway by the combined use of ultrasound and neurotrophic factors 
may be of clinical significance if applied sooner rather than many years after the emergence of 
PD manifestations.  Thus, this study has been specifically designed to address not only the 
usefulness of FUS in allowing the delivery of BBB-impermeant bioactive molecules, but also 
whether such combined strategy might be more efficacious in improving the quality of life in 
patients afflicted by a neurodegenerative disorder, if applied early. 
 
4.3 Materials and Methods  
In vivo experiments 
All experimental procedures involving animals were approved by the Columbia University 
Institutional Animal Care and Use Committee. Wild-type C57BL/6 mice (~25 g, ~3 months of 
age, sex: male, Harlan, Indianapolis, IN, USA) were group-housed under standard conditions (12 
hr light/dark cycles, 22°C) and were provided with a standard rodent chow (3 kcal/g; Harlan 
Laboratories, Indianapolis, IN, USA) and water ad libitum. A total of 70 animals received a daily 
injection of MPTP (30 mg kg-1 free-base) for five consecutive days; this regimen causes an 
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apoptotic degeneration of the nigrostriatal pathway in adult mice198 and by ~21 d after MPTP 
administration, no further loss of nigral dopaminergic neurons is detected. The groups and the 
corresponding timeline are summarized in Table II. 
 
Focused ultrasound  
A single-element, spherical-segment FUS transducer (center frequency: 1.5 MHz, focal depth: 60 
mm, radius: 30 mm; axial full-width half-maximum intensity: 7.5 mm, lateral full-width half-
maximum intensity: 1 mm, Imasonic, France), driven by a function generator (Agilent, Palo 
Alto, CA, USA) through a 50-dB power amplifier (E&I, Rochester, NY, USA) was used to target 
the SN and the CPu. A central void of the therapeutic transducer held a pulse-echo ultrasound 
transducer (center frequency: 10 MHz, focal depth: 60 mm, radius 11.2 mm; Olympus NDT, 
Waltham, MA) used for alignment, with their two foci aligned. The imaging transducer was 
driven by a pulser-receiver (Olympus, Waltham, MA, USA) connected to a digitizer (Gage 
Applied Technologies, Inc., Lachine, QC, Canada). A bolus of  0.1 μL/g of body mass 
polydisperse manufactured in-house29 microbubbles diluted in saline (8x108 #/ mL, mean 
diameter: 1.4 μm) was injected intravenously immediately preceding the sonication of each 
target, i.e. SN or CP. A 20-min time interval was allowed between SN and CPu targeting to 
allow the microbubble concentration to be cleared from the circulation199. Each animal was 
sonicated for 60 s, with a pulse repetition frequency (PRF) of 10 Hz, with one sonication location 
at SN and two sonication locations at the CPu in order to safely open the entire area of interest 
with acoustic parameters that do not cause damage, at peak negative acoustic pressure (PNP) of 
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day after the sonication to detect any potential damage using a  2D RARE sequence (TR/TE 
2500/10 ms/ms, echo train: 8, number of excitations: 8, field of view: 25.6mm × 25.6mm, 
resolution 100 μm  x 100 μm  x 400 μm). The sequences employed in this study have been 
previously optimized by our group94. 
 
Simulation 
The acoustic properties of the mouse head were obtained from microCT images with a resolution 
of 80 μm in the three directions (R_mCT2, Rigaku, Tokyo, Japan). The acoustic properties of the 
skull and the brain were obtained from previously published experimental data (35). The 
numerical simulations were performed using the k-Wave MATLAB (MathWorks Inc., Natick, 
MA, USA) toolbox200. The toolbox provides the k-space pseudo spectral time domain solution 
for the coupled first-order acoustic equations for heterogeneous media. The detailed explanation 
of simulation parameters can be found in our previous report201. 
 
Neurotrophic Factors  
Recombinant human Neurturin was purchased from Invitrogen (CA, USA) and reconstituted 
according to the manufacturer’s instructions. An intravenous injection of 50μl Neurturin (20 μg/g 
οf body mass) followed immediately after the FUS-induced BBB opening for which 5 μl/mouse 
microbubbles were diluted in 100μl saline and injected via the tail vein. 
 
The AAV1-CAG-eGFP-GDNF vectors used in this study were purchased from SignaGen 
Laboratories (Rockville, MD). The titers of the viral vectors were provided by the manufacturer 
(quantified with real-time PCR) and diluted to 1.2×1012 GC/ml in PBS. For each mouse (average 
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body weight of 25 g), a total of 100 μl diluted AAV was mixed with approximately 5 μl/mouse 
microbubbles and co-injected via the tail vein. 
 
AAV Transduction 
The mice were sacrificed and the brains processed similar to the previous description but, the 
sections were treated with rabbit anti-GFP antibody (dilution 1:5000, Novus Biologicals, 
Littleton, CO) and goat anti-rabbit conjugated with Alexa Fluor 488 (dilution 1:500, 
ThermoFisher, Waltham, MA) to confirm AAV transduction. Fluorescence images were taken 
with a confocal microscope (Nikon Instruments Inc., Melville, NY). 
 
Immunohistochemistry 
Mice were subjected to transcardial perfusion upon sacrifice and the brains extracted and 
sectioned (30 μm) throughout the entire CPu and SN as previously described169. Every 6th 
section of the posterior CPu and SN, and every 6th section of the anterior CPu were processed 
free-floating for TH-immunohistochemistry. After these sections were sequentially washed in 0.1 
M tris-buffered saline (TBS), treated with 10% methanol/3% H2O2 solution in TBS, rewashed in 
TBS, incubated for 60 min in 5% normal goat serum (NGS, Vector, USA), and then incubated 
for 49 h with an anti-TH antibody (Calbiochem, USA, 1:2000 for SN; 1:1000 for CPu) at 4oC in 
TBS containing 2% NGS. Then, sections were washed in TBS, followed by incubation for 60 
min with a secondary biotin-conjugated anti-rabbit antibody raised in goat (1:400 in TBS), 
washed again in TBS, incubated for 60 min in an avidin-biotin complex solution (ABC HRP kit 
(Peroxidase, Goat IgG), Vector Laboratories, USA) in TBS, and then washed in TBS. Finally, 
immunostaining was visualized by 3,3’-diaminobenzine (DAB substrate kit, Vector Labs) and all 
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sections were counter-stained with cresyl violet solution (1 g cresyl violet acetate, Sigma-
Aldrich, USA, in 500 mL DI-water with 25 mL acetic acid 10%).  
 
Real-time PCR 
Real-time PCR was used to quantify copies of GFP mRNA in various brain regions. Ten days 
after FUS-faciliated AAV delivery, mice were sacrificed and brain structures (striatum and 
substantia nigra) were isolated. The primers used in this study were forward (5’- 
AGCTGAAGGGCATCGACTTC-3’) and reverse (5’- CTACGGCTACCTTGTTACGA-3’). 
The analysis was performed with a RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). The 
mRNA levels were measured by qPCR using the SYBR Green assay (Applied Biosystems, 
Carlsbad, CA, USA). Signals from structures of interest were compared to signals from 
background tissue (cerebellum) and fold changes were obtained. 
 
High-performance Liquid Chromatography (HPLC)  
HPLC with electrochemical detection was employed to quantify the levels of dopamine, DOPAC 
and HVA. Following the same timeline for single NTN administration, mice (3-5 per group) 
were decapitated, their brains were quickly removed, hemispheres were separated and the 
corresponding sections (striatum and midbrain) were dissected out freehand on an ice-chilled 
glass petri dish. Samples were immediately frozen on dry ice and stored at -80˚C until analysis. 
On the day of the assay, the samples were sonicated in 50 vol (wt/vol) of HeGA while on ice. 
Centrifugation at 10,000 x g at 4°C for 10 minutes was followed by filtering and injection of the 
supernatant (20μl) onto a C18-reverse-phase HR-80 catecholamine column (ESA, Bedford, MA). 
The samples passed through a mobile phase of 90% 50 mM sodium phosphate/0.2 mM 
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EDTA/1.2 mM heptanesulfonic acid (pH = 3.5) solution and 10% methanol with a 1.0 ml/min 




The total number of TH- and cresyl violet-stained SNpc neurons were counted by Stereology 
using the optical fractionator as per the published protocols202,203. To quantify the 
immunoreactivity of TH+ nerve fibers in the SNpr, midbrain tissue sections were white-
balanced, and color deconvoluted112,204 prior to being converted to grayscale. Then, the SNpr was 
manually outlined, and the pixels within this region of interest were thresholded. The percentage 
of the dendrites/axons-covered area on each side, i.e. ipsilateral and contralateral to FUS, was 
determined and the average ratio of each group was used to compare the results among the 
different groups. The same quantification algorithm was followed for the TH+ expression in the 
CPu images without the deconvolution step since the striatum slices were not counterstained.  
 
Stereology 
Estimates of the number of TH+ neurons in the SNpc were generated by first delineating the 
borders of the SNpc with a 5× objective using the anatomical landmarks specified in the 
literature205,206. The number of SNpc TH+ (DA) neurons was then calculated using the optical 
fractionator probe (StereoInvestigator, version 11.02.1, MBF Bioscience, Williston, VT, USA). 
By applying a random start and random distribution of the counting frames, every 4th section 
was counted (for a total of ~10 sections per mouse) with an unbiased counting frame size of 100 
× 100 μm and a grid size of 200 × 200 μm. Cells were sampled through the entire thickness of 
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the tissue section using a 1 μm guard zone. Sections were viewed under a 40× dry objective.  At 
least 100 cells were counted within 40–60 framing sites for each side and animal, and the 
coefficient of error was ≤0.10. 
 
Behavioral Study  
Amphetamine-elicited behavioral studies were performed for the neurorestoration part of the 
experiments. Four weeks after MPTP lesioning, mice were randomly assigned to four groups. 
Each mouse received an intraperitoneal injection of amphetamine (2.5 mg/kg, dissolved in 150 μl 
saline) 10 min before behavioral testing. The subject was then placed in an open field chamber 
consisting of a custom-made polycarbonate chamber (dimensions: 27.3 cm x 27.3 cm x 27.3 cm). 
Directly above the chamber was a video camera, which interfaced with a computer and tracking 
software (Noldus, Wageningen, Netherlands). Each subject was placed directly in the center of 
the field, and video tracking was used to record and measure activity. Mice explored the field ad 
libitum for a session duration of 40 minutes. Upon completion, the subject was removed, urine 
and feces were counted and removed, and the chamber was cleaned with ethyl alcohol and 
disinfectants to remove any trace of the former subject. The same behavior testing was repeated 
for each animal post AAV/FUS treatment at the end of the 12-week survival period. 
 
Statistical Analysis  
Intra-group comparisons between the ipsilateral and contralateral sides were analyzed using a 
two-tailed paired Student’s t-test. All values are expressed as means ± standard deviation. 
Differences among group means were analyzed using two-way factorial analysis of variance 
(ANOVA) with AAV and FUS as the independent factors. When ANOVA showed significant 
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differences, pair-wise comparisons between means, post-hoc analysis by Newman-Keuls 
multiple comparisons test was performed. In all analyses, the null hypothesis was rejected at the 
0.05 level. All statistical analyses were performed using Prism 7 (Graphpad Software, San 
Diego, CA, USA). 
 
4.4 Results and Discussion  
To determine the potential value of using FUS to improve brain penetrance of bioactive 
molecules, especially those promoting functionality, if not viability, of the compromised neurons 
in certain regions of the neurodegenerated brain, we elected to use the MPTP mouse model of 
PD19. More precisely, not only does this neurotoxin-based model provide, in mice, reliable, 
extensively-validated lesioning of specifically the nigrostriatal DA pathway, but also causes, in 
humans, a clinical picture almost indistinguishable from PD21, hence strengthening the relevance 
of the anticipated mouse findings to the human condition. It should also be emphasized that most 
effective preclinical neuroprotective strategies tested in animal models of PD, while mitigating 
neurodegeneration, fail to maintain DA function207, hence often ending with a number of SNpc 
neurons unable to produce DA. Thus, the importance of identifying adjunct strategies that are 
capable of improving function in spared DA neurons is critical to the success of 
neuroprotective/neurorestorative strategies. Accordingly, our preclinical experiments were 
designed to be specifically relevant to this important clinical issue by using, primarily, TH-
immunostaining and quantitative morphology in the nigrostriatal DA pathway of mice post-
MPTP as a proxy for FUS allowing NTN and GDNF to reach and to operate within the CNS.  
This strategy was prompted by the fact that many spared DA neurons in the MPTP model have 
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subnormal expression of TH, the rate-limiting enzyme in DA synthesis, and that neurotrophic 
factors have the property of stimulating TH expression. 
 
For the present study, the workflow focused on the morphological quantification of cell bodies, 
dendrites and nerve terminals of the nigrostriatal DA pathway. Our experimental design 
compared TH-based parameters between hemispheres among MPTP-injected mice that received 
either no, one or three systemic injections of NTN combined with either one or three unilateral 
brain FUS exposures or a single gene delivery of AAV-GDNF; throughout this study, the 
ipsilateral hemisphere refers to the hemisphere receiving the unilateral ultrasound. Previously, 
we used a similar design in intact mice and found that the application of unilateral brain FUS 
following a systemic injection of another trophic factor, BDNF, did promote its entry into the 
brain, only in the ipsilateral hemisphere and in a highly regionally restricted manner70. In a 
similar rationale, the successful delivery of NTN through the FUS-induced BBB opening in wild 
type mice has been confirmed by tracing the downstream signaling pathway through the 
detection of increased phosphorylation of the Ret receptor, cytoplasmic kinase Erk 1 and 2 and 
CREB transcription factor in structures associated with their abundance112. Also, for the purpose 
of this study, the neurotrophic factors are assumed to be of equivalent efficacy when it comes to 
neurorestoration and neuroprotection as previously reported208,209.  
 
As we have previously demonstrated210, the regimen of MPTP used here in adult mice not only 
causes a loss of TH-positive cell bodies in the SNpc, but also, and to a greater extent, of TH-
positive dendrites in the substantia nigra pars reticulata (SNpr) and nerve terminals in the CPu 
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(Figure 18). Mice that were subjected to this subacute regimen of MPTP conformed to the 
 
Figure 17: The MPTP effect. a. The timeline shows degeneration following MPTP 
application and the interval until immunohistochemistry was performed. b. Representative 
coronal images of the SNc for control and MPTP injected groups. SNc cell body 
quantification for each brain hemisphere is presented. A ~22% reduction of SNc TH+ cell 
body number is observed in the MPTP- vs saline-injected mice (two-way ANOVA for n=7 , 
F[1, 12] = 3.191; P=0.0993). c. Higher magnification (4x) images focusing on the SNr shows 
a loss of fibers of ~33% in MPTP- vs. saline-injected mice (two-way ANOVA for n=5, F[1, 
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8] = 5.335; P=0.0497). The area quantification is presented per hemisphere and per brain. 
d. Representative images of the CPu TH+ terminal density for the saline and MPTP groups 
showing a ~40% reduction of CPu TH+ immunoreactivity in MPTP- vs saline-injected 
mice (two-way ANOVA for n=5, F[1, 8] = 25.64; P=0.0010). Area quantification shows the 
decrease in TH+ immunoreactivity for the MPTP mice per side per brain. 
known description of the aforementioned brain lesion. However, based on our past experience210, 
we specifically set the dosage of MPTP per injection to cause a detectable but minimal reduction 
in TH-positive neurons in the SNpc so that we could predict a 40-50% reduction in TH-
immunoreactivity in the CPu. This approach was selected since goal for this work was to closely 
emulate an early stage of PD19. Indeed, the ultimate objective of the proposed methodology 
would be for application in early stage PD patients who may experience a particularly strong 
quality of life improvement, should the proposed therapeutic strategy effectively boost the 
expression of DA synthetic enzymes, such as TH, in compromised, but still alive SNpc neurons. 
As expected, our stereology counts revealed a ~23% reduction of SNpc TH-positive neurons in 
mice injected with MPTP compared to those injected with saline (two-way ANOVA for n=7, 
F[1, 12] = 3.191; P=0.0993). To assess the effect of MPTP in the SNpr and CPu, we used a 
customized TH density quantification algorithm based on thresholding. Images were white-
corrected and color-deconvoluted before delineating the SNpr or the CPu as the ROIs. The 
percentages of pixels over the ROIs that exceeded the set intensity threshold for both MPTP- and 
saline-injected mice are presented for both hemispheres separately. Based on this method, we 
found that MPTP-injected mice displayed a ~35% and ~45% reduction of TH-immunoreactivity 
in the SNpr (two-way ANOVA for n=5, F[1, 8] = 5.335; P=0.0497) and CPu (two-way ANOVA 
for n=5, F[1, 8] = 25.64; P=0.0010), respectively (Figure 18). Furthermore, neither in the MPTP-
treated (pair Student’s t-test; SNpc: t[6]=0.821, p=0.442; SNpr: t[4]=0.07, p=0.947; CPu: 
t[4]=1.832, p=0.14) nor in the saline-administered mice (pair Student’s t-test; SNpc: t[6]=0.217, 
p=0.835; SNpr: t[4]=1.447, p=0.221; CPu: t[4]=0.426, p=0.691) did the DA parameters differ 
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significantly between the two hemispheres, excluding TH-immunoreactivity asymmetry. The 
significant loss of cells bodies, dendrites and terminals in the MPTP brains was also noted by the 
decreased TH immunoreactivity compared to the saline group. 
 
Having established the damage caused in the three selected brain regions, i.e. SNpc, SNpr, and 
CPu by the MPTP injections, we then investigated the effects of the combination of a unilateral 
brain FUS application with the systemic administration of NTN on DA parameters in MPTP 
mice.  
 
Given the lack of right-left DA asymmetry in the MPTP mice reported above and the fact that 
FUS is applied only on one side of the brain, our results were computed as ratios of ipsilateral 
over contralateral values to better capture the unilateral nature of the proposed strategies.  
 
Since the cell bodies of the nigrostriatal DA neurons reside in the SNpc, assessment of the effect 
of FUS/NTN in this specific brain region was first performed in order to understand the potential 
effect of our methodology on a stable lesion, i.e. fixed number of neurons. Indeed, at the selected 
time point, it has been demonstrated previously that DA neurons no longer die211. Since no 
compelling evidence of DA neurogenesis in the post-lesioned adult brain exists212, any change in 
the number of TH-positive neurons could only be attributed to a larger number of “countable 
neurons” due to increased TH immunoreactivity. This phenomenon, thus, works as a proxy for  
NTN action. Two descriptive timelines show the steps followed during the experimental 
procedure for the single and triple treatment separately, along with the representative TH-
immunostained tissue sections (Figure 19). A one-way ANOVA for the five groups of MPTP-
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injected mice, i.e. FUS-/NTN-, FUS+/NTN-, FUS+++/NTN-, FUS+/NTN+, and 
 
Figure 18: Neurorestoration effect at the level of the SN. a. Single treatment at the SN: The 
descriptive timeline of the procedure is followed by representative TH 
immunohistochemistry images. The plus/minus signs indicate whether the corresponding 
side of the brain received MPTP, FUS and NTN. b. Triple treatment at the level of the SN: 
The corresponding timeline provides information regarding the additional steps followed 
for this part of the study. The plus/minus signs indicate whether the brains received MPTP, 
FUS and NTN and the three plus signs denote the times the treatment was repeated. c. Cell 
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body counts at the level of the SNc region. Results are shown as the relative ratio by 
dividing the contralateral side into the ipsilateral side. The statistical significance occurs 
with one-way ANOVA (n=5-7; F[4, 27] = 8.892; P=0.0001) after correcting the multiple 
measurements with Newman-Keuls method. d. The area quantification of the fibrotic 
density at the SNr region. The results are shown as the relative ratio by dividing the 
contralateral side into the ipsilateral side. The statistical significance occurs with one-way 
ANOVA (n=5-7; F[4, 22] = 11.31; P<0.0001) after correcting the multiple measurements 
with Newman-Keuls method. 
FUS+++/NTN+++, revealed significant differences in SNpc TH-positive neuron numbers (n=5-
7; F[4, 27] = 8.892; P=0.0001). By using Newman-Keuls post-hoc tests, we found that either one 
or three FUS applications to MPTP mice alone failed to significantly increase TH-positive SNpc 
neuron numbers compared to no FUS (P>0.05). Conversely, administration of three, but not one, 
NTN administrations, each time preceded by FUS application, resulted in a significant increase 
(p<0.01) on the order of 17%.  Thus, these findings indicate that systemic NTN successfully 
gained access to the CNS following FUS application and initiated the upregulation of TH 
expression within the spared SNpc DA neurons. Although these results are encouraging, from a 
functional standpoint, it remains to be investigated whether similar changes occurred where DA 
neurotransmission actually takes place.  
 
One unique property of SNpc DA neurons is the capacity to release DA from their dendrites, 
suggesting that DA mediates neurotransmission events not only at the level of the CPu but also at 
the level of the SNpr. Thus, to address the effect of NTN in the SNpr region, the threshold area 
covered by TH-positive fibers exceeding the stain-intensity cut-off was extracted and normalized 
to the entire region covered by fibers. As for the SNpc, a one-way ANOVA revealed significant 
differences in SNpr TH-positive fiber density among the five groups (F[4, 22] = 11.31; 
P<0.0001) as shown in Figure 19. As was the case with the cell bodies, the Newman-Keuls post-
hoc test demonstrated that neither one nor three FUS applications alone to MPTP mice produced 
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any positive changes in SNpr fiber density. In contrast, both single and triple administration of 
NTN, after the corresponding applications of FUS, resulted in a statistically significant increase 
of the SNpr TH-positive dendritic network on the order of 20-22% compared to the no FUS 
group. The higher TH-immunoreactivity observed within the SNpr in response to FUS/NTN 
treatment supports the notion that dendritic expression of DA markers in spared neurons post-
MPTP can be increased.  
 
Furthermore, given that TH is the rate-limiting enzyme in DA synthesis, our results support the 
fact that the combination of NTN and FUS may help to enhance DA neurotransmission in 
compromised neurons. Interestingly, if enhanced DA neurotransmission within the SNpr can be 
associated with comparable changes in the CPu, the proposed therapeutic strategy may have far-
reaching implications for the symptomatic treatment of PD. It is also worth noting that since the 
magnitude of the changes was not significantly different in MPTP-injected mice that received 
one or three FUS/NTN treatments, it may be argued that, with respect to SNpr, the maximal 
induction of TH in the DA dendrites is already achieved after a single FUS/NTN exposure. 
However, from the perspective of a chronic condition like PD, future studies will have to 
investigate the duration of the dendritic induction of TH produced by one and three FUS/NTN 
exposures and assess the recurrence of the treatment, as this question may be of major 
importance in determining the optimal FUS/NTN regimen for PD patients.  
 
Anatomically, SNc DA neurons project primarily to the CPu19, hence the loss of SNpc DA 
neurons in PD causes a striatal depletion of DA nerve terminals and DA content. To determine 
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the efficacy of our technique in promoting nerve terminal function, we estimated CPu fiber 
 
Figure 19: Neurorestoration effect at the Caudate-Putamen (CPu) region. a. The 
descriptive timeline of the procedure is followed by representative TH 
immunohistochemistry images. The pixels surpassing a certain threshold are presented in 
dark red to enhance the differences between the ipsilateral and contralateral side.  The 
plus/minus signs indicate whether the corresponding side of the brain received MPTP, FUS 
and NTN. b. Triple treatment at the CPu: The corresponding timeline provides 
information regarding the additional steps followed for this part of the study. The 
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plus/minus signs indicate whether the brains received MPTP, FUS and NTN and the three 
plus signs denote the number of times the treatment was repeated. c. The area 
quantification of the terminal density at the CPu region. Results are shown as the relative 
ratio by dividing the contralateral side into the ipsilateral side. The statistical significance 
occurs with one-way ANOVA (n=5-7; F[4, 24] = 3.527; P=0.0212) after correcting the 
multiple measurements with Newman-Keuls method permeate the CPu as effectively as in 
the SNr, it may be that the stronger regimen of FUS/NTN is required to achieve the desired 
effect. Furthermore, within the CPu, TH-positive fibers represent less than 10% of the 
fiber pool hence, most of the NTN molecules in the CPu might interact with neuronal 
structures other than TH-positive fibers. 
density by quantifying its TH immunoreactivity employing the same algorithm as for the SNpr 
site. Figure 20 shows the respective timelines with the sonicated structure as well as 
representative images for each group. Again, we performed a one-way ANOVA which revealed 
significant differences in the CPu TH-positive fiber density among the five groups (n=5-7; F[4, 
24] = 3.527; P=0.0212).  As expected, from the preceding analysis of the SN regions, FUS alone 
did not result in an increase of the terminal TH positivity. In striking contrast to the situation 
observed in the SNpr, only the three FUS/NTN exposures caused an overt increase in TH 
immunoreactivity in the CPu of the MPTP mice (p<0.05) on the order of 50%. Since the single 
administration of NTN failed to permeate the CPu as effectively as in the SNpr, the stronger 
regimen of FUS/NTN may be required to achieve the desired effect. Furthermore, within the 
CPu, TH-positive fibers represent less than 10% of the fiber pool hence, most of the NTN 
molecules in the CPu might interact with neuronal structures other than TH-positive fibers. To 
complement these immunohistochemical findings, the levels of DA and its metabolites, 
homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were determined by 
HPLC in both the ventral midbrain and striatum. The results are reported as ratios of ipsilateral 
over contralateral levels to capture the unilateral effect of our intervention. A significant twofold 
increase in DA levels was observed in the ventral midbrain (F[3, 13] = 7.055; P=0.0047) and to a 
lesser extend in the CPu of hemispheres treated once with ultrasound and NTN compared to the 
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rest. The levels of the key metabolites followed the same trend, even though these changes in 
metabolites were not statistically significant. These HPLC findings are in agreement with the TH 
immunoreactivity proving the insufficiency of the single treatment in restoring the depleted DA 
to its original levels.  
 
The decrease in TH immunoreactivity observed in MPTP-injected mice treated with ultrasound 
alone (FUS+/NTN- and FUS+++/NTN-) in Figures 19 and 20 raised the possibility that FUS 
might downregulate TH expression. To test this possibility, naïve mice (i.e. not injected with 
MPTP) were subjected to FUS. For this experiment, five mice sonicated multiple times (MPTP-
/FUS+++/NTN-) and five mice sonicated only once (MPTP-/FUS+/NTN-) were compared 
against five control mice (MPTP-/FUS-/NTN-); for the three sonications protocol, two days 
interval was used between each sonication to allow the BBB to be restored94. Remarkably, the 
number of SNpc TH-positive neurons did not significantly differ among the three groups (one-
way ANOVA, F[2, 12] = 1.755; P=0.2145). Similarly, no significant differences were observed 
in either the SNpr TH-positive dendrite (one-way ANOVA, F[2, 12] = 0.1158; P=0.8917) or CPu 
TH-positive terminal density (one way ANOVA, F[2, 12] = 0.1193; P=0.8886) across the three 
groups. Although FUS does not cause any detectable alteration in TH expression in healthy 
neurons, it remains an open question whether ultrasound could downregulate TH expression in 
compromised neurons. 
 
To determine whether dopaminergic restorative effects could be produced by the combination of 
AAV-GDNF and FUS in the early stages of PD, a new cohort of mice was used and the different 
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treatments (FUS-/AAV-, FUS+/AAV-, FUS-/AAV+, FUS+/AAV+) were compared 84 days 
after the delivery (Figure 21a).  
 
The viral vector used in this study was AAV1 under the control of the neuron-specific CAG 
promotor. Different from AAV9, a more aggressive serotype, AAV1 does not cross the BBB 
spontaneously, and yet maintaining a higher level of bioactivity compared to that of AAV2. Our 
previous work has shown that greater transduction can be achieved using this serotype compared 
to AAV276, which has been the sole choice for all clinical PD trials to date213. The CAG 
promotor was selected to best represent the vector used in prior clinical trials. In this study, we 
observed some degree of non-specific transductions in untargeted organs, such as the liver and 
kidney similar to neuron-specific promotor synapsin213,214.  
 
Upon sacrifice, immunohistochemistry revealed stronger TH immunopositivity at the level of the 
ventral midbrain sections of MPTP mice receiving AAV+/FUS+ combinations, on the sonicated 
side, than at the level of ventral midbrain sections of mice from all other MPTP groups (Figure 
21b). Quantitatively, TH-positive neuron numbers did not significantly differ (paired Student’s t-
test; t[7] ≤ 0.45, p ≥ 0.67) in mice that received neither or one form of treatment (i.e. AAV or 
FUS) as shown in Figure 21c. However, while marginal, MPTP mice that received systemic 
AAV-GDNF injection and unilateral sonication showed, on average, a greater number of SN 
TH-positive neuron numbers on the sonicated side (paired Student’s t-test; t[11] = 2.93, p = 
0.015). Even more striking is the observation that MPTP mice from the AAV+/FUS+ group 
showed, on the sonicated side, quite a stronger SN pars reticulata optical density of TH 
immunostaining (Figure 21d and 21e) (paired Student’s t-test; t[4] = 7.01, p = 0.006), suggesting 
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Figure 20: FUS-facilitated AAV-GDNF delivery induced neuronal upregulation in MPTP 
mice. a. Experimental timeline where MPTP was given first followed by sonication and a 
12-week survival period. Behavioral studies were performed 1 week prior to sonication and 
repeated at the end of the survival period. b. TH staining of the SN region in mice receiving 
a combination of AAV/FUS treatments (n=6-10). c. TH+ neurons were counted and intra-
group comparisons were made. Significantly higher number of TH+ neurons were found 
on the AAV+/FUS+ side of the brain compared to the contralateral side. d. TH+ dendrite 
density was calculated and intra-group comparisons were performed. Significantly higher 
dendrite density was observed on the AAV+/FUS+ side of the brain. e. Immunofluorescent 
TH staining revealed much more dopaminergic projections on the AAV+/FUS+ side of the 
brain. Dendritic densities of the SN region were compared across groups and significantly 
higher dendritic fiber network (n=4-5; F[3, 13] = 7.514; P=0.0036) was identified 
comparing  AAV+/FUS+ to the MPTP group. f. TH staining of the striatum illustrates the 
ameliorated dopaminergic projections on the AAV+/FUS+ hemisphere. Quantitative 
analysis of the optical density ratio demonstrated significant difference (n=4-5; F[3, 17] = 
4.733; P=0.014) between the AAV+/FUS+ to the MPTP group. g. Amphetamine-elicited 
behavioral studies revealed more frequent clockwise (toward the remaining lesion side) 
rotation, signifying more prominent dopaminergic function on the hemisphere receiving 
AAV+/FUS+ treatment. 
dendrites. Across group comparison revealed a significant  increase (n=4-5; F[3, 13] = 7.514; 
P=0.0036) on the order of 76% in the dendritic fiber network of the ipsilateral-over-contralateral 
side compared to the MPTP group (Figure 21e). A very similar situation was observed for the 
ratio of the striatal TH-positive terminal density which was significantly higher (n=4-5; F[3, 17] 
= 4.733; P=0.014) on the order to 32% for the AAV+/FUS+ group compared to the MPTP-
injected mice (Figure 21f). 
 
To provide a functional correlate to the above results, we took advantage of the fact that 
amphetamine, by stimulating the release of dopamine from the residual neurons, induces a 
rotational behavior in rodents if there is a right/left unbalance215. Using a camera-based 
behavioral testing apparatus, mice were allowed to explore the field freely and the number of 
clockwise (CW; i.e. away from the sonicated hemisphere) and counter-clockwise rotations 
(CCW; toward the sonicated hemisphere) were recorded after amphetamine injection. After 
MPTP injection but prior to any AAV and/or FUS treatment, no significant rotational behavioral 
81 
 
was noted in any of the mice indicating that the MPTP lesion produced symmetrical damage. 
Twelve weeks after the AAV and/or FUS treatment, only the MPTP mice from the AAV+/FUS+ 
group showed significant rotations that were consistently CW (paired Student’s t-test; t[8] = 
2.61, p = 0.035), supporting the notion that the sonicated side was associated with higher 
amphetamine-induced dopaminergic neurostimulation (Figure 21h).  
 
The AAV+/FUS+- treated mice had significantly higher optical densities for both the dendritic 
field in the SN pars reticulata and the nerve terminal network in the CPu, on the sonicated side as 
well as a marginal increase in SN TH-positive neurons on the sonicated side. Since no 
compelling evidence exists, supporting that novel dopaminergic neurons can be produced in 
mature brains207, the most parsimonious explanation for the AAV/FUS-related changes in 
neuronal counts is that the combined treatment stimulates the expression of TH, causing merely 
more dopaminergic neurons to become identifiable and counted. Although this explanation can 
also apply to the dendritic field changes, we cannot exclude that the nerve terminal changes are, 
at least, due to axonal sprouting. While more work is required to elucidate the underpinning 
process driving the aforementioned changes, we already know that they are functionally relevant 
since, following amphetamine injection, the MPTP mice post-treated with AAV/FUS display a 
robust rotational behavior consistent with the idea that the sonicated side that received AAV-
GDNF recovered a strong dopaminergic neurotransmission215. 
 
The therapeutic alternatives explored in this study showed a gradual increase in beneficial 
outcome. Direct protein delivery was proven efficient in upregulating neuronal function but its 
translation to the clinical practice entails multiple applications that significantly improve 
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neuronal integrity along the entire pathway. Gene therapy comes as an alternative to multiple 
applications allowing for constant release of the neurotrophic factor with only one ultrasound 
session. The successful delivery was followed not only by upregulation of the dopaminergic 
pathway including a small increase in neuronal cells but also by a detectable behavioral effect 
enhanced by the administration of amphetamine.  
 
4.5 Limitations and Conclusions  
One limitation of this study is that FUS could induce acute inflammation in the sonicated 
region53. This is likely caused by the exudates (such as albumin) through the opened BBB 
leading to microglia upregulation. However, as shown in our previously reported studies, this 
does not lead to long-term inflammation nor behavior deficits76. The amount of administered 
viral vectors should also be carefully examined to minimize systemic toxicity and immune 
response. Studies in larger animal models (i.e. non-human primates) need to be carried out 
before results presented here can be translated to the clinic.  
 
Other limitations in this study include the limited number of mice used primarily due to the high 
cost of NTN acquisition. As a consequence, additional quantitative measures to directly measure 
DA synthesis such as analytical techniques could not be fully explored but will be included in 
future studies. Moreover, different dosages, upregulation duration as well as the time-interval 
between consecutive treatments also could not be studied. Multiple treatments may have an even 
more profound restorative effect, if applied at the steady state of the preceding treatment. The 
two major obstacles involved in NTN delivery to the brain with efficient dosage lie in, first, 
permeating the BBB and, second, ensuring sufficient bioavailability across the entire structure of 
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interest. In the study preceding this one192, it was shown that both objectives could be achieved 
with FUS-induced BBB drug delivery in wild-type mice. 
 
In conclusion, for the first time, our findings show that by targeting the SN and CPu at the early 
stages of PD, the nigrostriatal pathway is upregulated, thus reinforcing the strong premise of 
FUS methodology for allowing otherwise BBB-impermeant bioactive molecules to reach the 
brain parenchyma and treat the compromised neurons. Administration of neurotrophic factors 
achieved significant increase in the DA phenotypic marker TH that was localized at the level of 
the downregulated nigrostriatal pathway. Gene therapy and the triple treatment improved 
neuronal function at both the dendritic and terminal area while the single treatment only 
upregulated the former.  
 
This study employed direct delivery of neurotrophic proteins as the pharmacological strategy, 
therefore substituting gene delivery and the associated risks. On the other hand, gene delivery 
was proven safe and beneficial to the treated brains accounting as a viable alternative to the 
difficulties associated with multiple treatments. The AAV-GDNF delivery offered the 
opportunity of investigating physiological changes due to the continuous production of the 
neurotrophic factor and the longer survival times constituting the second part of this study. Based 
on these initial findings, FUS-mediated neurotrophic protein delivery may prove pivotal in the 
effective reversibility of neurodegeneration at the early stages of the disease where motor control 
symptoms are most prominent. The study also concluded that repeated protein delivery, similar 
to gene therapy, improves neuronal function along the entire pathway, further demonstrating the 
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Previous studies have confirmed the safe and reversible BBB disruption in the striatum and 
midbrain of wild type mice allowing the penetration of neurotrophic factors that subsequently 
triggered downstream effects76,112. In this chapter, we showed for the first time that single and 
multiple administrations of NTN upregulate respectively the depleted nigrostriatal pathway in 
the MPTP mouse model. Direct protein delivery is followed by viral vectors GDNF delivery that 
improves neuronal function similar to multiple NTN administrations.  
 
The overall contribution of this study was the characterization, in terms of the increase in the 
tyrosine hydroxylase (TH) phenotypic marker and the associated physiological changes, of 
possible therapeutic alternatives in upregulating the dopaminergic activity in the Parkinsonian 
mouse brain. MPTP was confirmed to suppress TH immunoreactivity in the CPu and midbrain 
under a sub-acute regime. Direct protein delivery upregulated the depleted DA neurons in the SN 
region while only repeated direct protein delivery managed to stimulate the DA terminals in the 
CPu. Gene delivery was found to upregulate the depleted DA neurons in both the SN and CPu 
comparably to repeated delivery. The results of the studies described in this chapter have been 
published in peer reviewed scientific journals66,216. 
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Chapter 5: Focused ultrasound-induced blood-brain barrier 
opening initiates pathological changes in two different Alzheimer’s 
mouse models. 
In chapter 4, we explored the beneficial outcomes of neurotrophic delivery in transgenic animals. 
An open question that emerged from the application of FUS-induced BBB opening as a drug-
delivery strategy was the percent of ultrasound contribution to the overall beneficial effect.  The 
immonumodulatory effect of FUS-induced BBB opening will be explored in this chapter under 
the prism of pathological amelioration in two Alzheimer‘s mouse models. Once establishing the 
effect of ultrasound application in the isolated tau pathology, we will then explore the sonication 
outcomes in brains suffering from the simultaneous presence of amyloid and tau that resembles 
greatly the human AD pathology. 
 
5.1 Unilateral focused ultrasound-induced blood-brain barrier opening reduces 
phosphorylated tau from the rTg4510 tauopathy mouse model.  
5.1.1 Abstract  
The neuropathological hallmarks of Alzheimer’s disease include amyloid plaques and 
neurofibrillary tangles. Tau pathology correlates well with impaired neuronal activity and 
dementia. Focused ultrasound coupled with systemic administration of microbubbles has 
previously been shown to open the blood-brain barrier and induce an immune response, which, 
in an amyloid AD mouse model, resulted in the reduction of the amyloid brain load. In this 
study, we investigated the effect of focused ultrasound at the early stages of tau pathology (pre-
tangle) in the rTg4510 mouse model. Reduction of phosphorylated tau from the hippocampal 
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formation processes, and particularly the pyramidal CA1 neurons, was noted in the ultrasound-
treated brains without an associated increase in the phosphorylated tau-affected cell somas, 
typically associated with disease progression. Attenuation of the pathology was found to 
correlate well with the ultrasound-initiated immune response without compromising neuronal 
integrity. Unilateral ultrasound application resulted in a bilateral effect indicating a broader 
reduction of the phosphorylated tau. Findings presented herein reinforce the premise of 
ultrasound in reducing tau pathology and thus curbing the progression of Alzheimer’s disease. 
 
5.1.2 Introduction 
As previously described, Alzheimer’s disease’ defining features include changes in the brain 
histology and behavior microscopically described by the combinatorial presence of amyloid 
plaques and neurofibrillary tangles13. From clinical standpoint, the cornerstone in prevention and 
management of Alzheimer’s disease is the deceleration of the progression through non-
pharmacological approaches -behavioral techniques and adjusted nutrition- and pharmacological 
agents targeting cognition enhancement and systemic complications management10. Clinically, 
several phase III trials have been performed in patients with mild-to-moderate Alzheimer’s 
disease but failed to show significant improvement in their primary outcomes217,218. It was only 
until four years ago that the phase 1b clinical trial administering aducanumab in Aβ PET-positive 
patients (prodromal or mild AD) reported on reduced levels of Aβ in a dose- and time-depended 
regime, yet the trial was not valued for the clinical endpoints given the observational nature of 
the data and the missing corrections in the statistics219. Finally, the emerging technology of FUS 
was recently evaluated in terms of its clinical safety and feasibility in five early-to-moderate 
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Alzheimer’s patients, succeeding in inducing a transient BBB opening5 without adverse 
effects116. 
 
FUS has been evaluated in experiments involving the safe BBB disruption of various animal 
species including rodents, lagomorphs and primates26,27,51,119 and in different disease-mimicking 
models61,62,64,67. FUS-induced BBB opening was initially introduced as a surrogate to drug 
delivery techniques that fell short in efficaciously surpassing the hindrances posed by the BBB 
hence their invasive and/or non-targeted nature25. Specifically in Alzheimer’s disease, antibodies 
against Αβ61,220 have been mediated into the brain parenchyma by FUS, which resulted in the 
amyloid plaque load reduction. More importantly, these studies showed that amyloid could be 
cleared even in the absence of the antibody indicating the immense potential of FUS-facilitated 
BBB opening as an immunomodulatory stimulant. Transcriptomic analysis of the FUS-induced 
bioeffects outlined the profile of the triggered acute inflammation. Aside from forming an 
environment that could favor neuro- and angiogenesis, FUS-induced BBB opening was proven 
to contribute to the clearance of pathological proteins221 accounting microglia activation as part 
of the response61,62.  
 
The role of microglia in neurodegenerative diseases remains a challenging topic. Although 
microglia respond immediately to acute injury, morphologically activated microglia for an 
extended period of time fail to synthesize inflammatory mediators that could negatively impact 
neuronal integrity80. Prolonged activation of microglia is present in chronic neurodegenerative 
disorders, yet efforts to inhibit inflammatory mediators secreted by microglia failed to ameliorate 
the degeneration80. In Alzheimer’s disease, microglia acquire an “activated” phenotype yet fail to 
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reduce amyloidosis81, while the link between microgliosis and tau pathology remains to be 
established79,82. Stimulus-dependent conformational changes and dystrophic microglia have been 
associated with tau pathology, while re-programming of the microglia to healthier phenotypes 
has recently emerged as a therapeutic strategy83,84.  
 
Whether FUS-induced BBB opening using a safely tolerated paradigm61,62 could drive an 
immune response characterized by the activation of microglia53, and/or infiltration of peripheral 
immune cells51,53,222 such as macrophages and monocytes to help ameliorate such pathologies, 
remains unclear but these mechanisms could explain the positive effects observed. Recently, a 
decrease in phosphorylated tau from the entorhinal cortex in a human-tau mutant transgenic 
mouse strain (line pR5) has been reported following antibody delivery by repeated FUS-
mediated BBB opening over the entire brain64. However, the interaction of FUS with tau 
pathology has not been studied from the immunotherapeutic angle. 
 
We have now examined whether early-stage tau pathology can be attenuated by ultrasound to (i) 
investigate the efficacy of unilateral FUS, as an adjuvant treatment, for the reduction of 
phosphorylated human tau in the hippocampus of the rTg4510 mouse model of AD and (ii) 
identify the response of the FUS-initiated immune reaction to the pathology. 
 
5.1.3 Materials and Methods  
In vivo experiments 
For this study 13 male mice of the rTg4510 line (overexpressing human tau pathology) were 
included, 10 at the age of 3.5 months and 3 at the age of 4.5 months. The same age animals were 
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randomly assigned to the sham and sonicated groups (five mice per group) while the older mice 
were utilized in the optimization and validation of the algorithms. Animals were group-housed 
under standard conditions (12 hr light/dark cycles, 22oC), were provided with a standard rodent 
chow (3 kcal/g; Harlan Laboratories, Indianapolis, IN, USA) and water ad libitum. All 
procedures involving animals were approved by the Columbia University Institutional Animal 
Care and Use Committee. 
 
All mice involved in the study (sham and sonicated) were anesthetized with a mixture of oxygen 
and 1-2% isoflurane (SurgiVet, Smiths Medical PM, Inc.,WI), placed prone with the head 
immobilized by a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA) and depilated to 
expose the suture anatomy and minimize acoustic impedance mismatch. Identification of the 
parietal and interparietal bone intersection enabled proper positioning of the transducer following 
a grid-guided targeting procedure27. Targeting the hippocampal formation involved positioning 
of the transducer 3 mm anteriorly to the lambdoid suture, and 1.5 mm laterally towards the left 
hemisphere to cover the dorsal part, while 2 mm anteriorly and 3.2 mm laterally for the ventral 
part. A bolus of 0.1 μL/g of body mass polydisperse manufactured in-house29,199 microbubbles 
diluted in saline (8x108 #/ mL, mean diameter: 1.4 μm) was injected intravenously, in all mice, 
immediately preceding the sonication.  
 
Five mice (3.5 months old) were sonicated for 60 s, with a pulse length of 6.7 ms and a repetition 
frequency of 10 Hz at PNP of 0.45 MPa after accounting for 18% murine skull attenuation. 
Acoustic emissions were monitored in real time43 to assess the degree of cavitation. The 
remaining five mice at 3.5 months of age and the 4.5 months old animals were subjected to the 
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procedure without triggering the transducer (sham groups). All animals underwent magnetic 
resonance imaging for BBB opening confirmation and safety assessment. The same procedure 
was repeated once per week for four consecutive weeks while the animals survived for one day 
after the last treatment prior to sacrifice. 
 
Focused ultrasound  
A single-element, spherical-segment FUS transducer (center frequency: 1.5 MHz, focal depth: 
60mm, radius: 30mm; axial full-width half-maximum intensity: 7.5 mm, lateral full-width half-
maximum intensity: 1 mm, Imasonic, France), driven by a function generator (Agilent, Palo 
Alto, CA, USA) through a 50-dB power amplifier (E&I, Rochester, NY, USA) was used to target 
the hippocampus. A needle hydrophone (HGL-0400, Onda Corp., Sunnyvale, CA) was used for 
the transducer calibration, which measured the acoustic beam profile in a tank filled with 
degassed water. A central void of the therapeutic transducer held a pulse-echo ultrasound 
transducer (center frequency: 10 MHz, focal depth: 60mm, radius 11.2 mm; Olympus NDT, 
Waltham, MA) used for alignment, with their two foci aligned. The imaging transducer was 
driven by a pulser-receiver (Olympus, Waltham, MA, USA) connected to a digitizer (Gage 
Applied Technologies, Inc., Lachine, QC, Canada). A cone filled with degassed, distilled water 
was mounted onto the transducer assembly. The transducers were attached to a computer-
controlled 3D positioning system (Velmex Inc., Lachine, QC, Canada).  
 
Magnetic resonance imaging 
Following the ultrasound procedure, all animals underwent scanning with the 9.4T MRI system 
(Bruker Medical, Boston, MA). The mice were placed in a birdcage coil (diameter 35 mm), 
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while being anesthetized with 1 – 2% isoflurane and respiration rate was monitored throughout 
the imaging sessions. MR images were acquired using a contrast-enhanced T1-weighted 2D 
FLASH sequence (TR/TE 230/3.3 ms/ms, flip angle: 70°, number of excitations: 6, field of view: 
25.6 mm × 25.6 mm, resolution 100 μm  x 100 μm  x 400 μm), 30 minutes following the 
intraperitoneal bolus injection of 0.3 ml gadodiamide (GD-DTPA) (Omniscan, GE Healthcare, 
Princeton, NJ). As previously reported, gadodiamide provides spatial information of the BBB 
opening by temporally enhancing the MR signal relative to the ultrasound parameters37. In 
addition, T2-weighted MRI was performed one day after the sonication to detect any potential 
damage using a  2D RARE sequence (TR/TE 2500/10 ms/ms, echo train: 8, number of 
excitations: 8, field of view: 25.6 mm × 25.6 mm, resolution 100 μm  x 100 μm  x 400 μm). The 
sequences employed in this study have been previously optimized by our group94. 
 
Immunohistochemistry 
All animals were transcardially perfused (30 mL PBS followed by 60 mL 4% paraformaldehyde) 
one day after the last treatment. The brains were extracted, immersed in PFA fixative for 24 h 
and then in 30% Sucrose for at least 2 days prior to freezing. After brains were frozen on dry-ice, 
cryostat-cut coronal hippocampal sections (35 μm) were collected in anti-freezing solution. 
Then, 2-3 free-floating sections of the dorsal hippocampus with a 6-sections gap were processed 
for immunohistochemistry. The sections were sequentially washed in 0.1M PBS, treated with 5% 
donkey serum in 0.3% PBST for thirty minutes with the addition of mouse seroblock for the last 
ten minutes followed by overnight incubation at 4oC with the primary antibodies: i. mouse anti-
human-phospho-tau (AT8, 1:500, Sigma) and rabbit anti-CD68 (1:500, abcam), ii. mouse anti-
human-phospho-tau (AT8, 1:500, Sigma) and rabbit anti-Iba1 (1:500, abcam), iii. mouse anti-β-
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tubulin III (1:500, Sigma) and rabbit anti-NeuN (1:500, abcam) antibodies. Then, sections were 
washed in PBS and incubated for 60 min in 0.3% PBST with 5% donkey serum containing the 
respective donkey-raised secondary antibodies, Texas Red-, Alexa488- and Alexa405-conjugated 
(1:1000). After the incubation, the sections were washed again in PBS and mounted on slides. 
The slides were merged into 0.3% sudan black for five minutes, rinsed with 70% ethanol, 
washed three times with 0.02% Tween20 in PBS and treated with Hoechst 33342 (5 μm/ml) for 
ten minutes, when cell visualization was necessary. Finally, the slides were washed with PBS 
and cover slipped with Fluoromount solution. 
 
Confocal microscopy 
The large field confocal images of the hippocampus were captured on a 20× objective of a Nikon 
confocal microscope (Nikon Instruments Inc., Melville, NY, USA) with the same exposure 
parameters for the lasers. Tile (mosaic) and a Z-stack (2 μm step, 7 series) were necessary were 
acquired and processed with ImageJ to produce the resulting maximum intensity image. For 
colocalization assessment, three single-tile and non-overlapping images covering the CA1 region 
were captured on a 60× objective of the same microscope. The acquired Z-stack (1 μm step, 13 
series) was analyzed with ImageJ to construct the orthogonal views12 and the corresponding 
video included in the Supplementary Material. Custom algorithms in MATLAB (R2017a, 






The enhancement in the horizontal plane of MR images was quantified by volumetric analysis 
encompassing the hippocampal formation37. Two same-size ellipsoidal ROIs were constructed, 
covering the targeted the contralateral sides. The sum of the pixels in the ipsilateral ROI 
surpassing the mean value of the contralateral ROI yielded the area of the BBB opening while 
performing the same analysis in 17 consecutive slices, matching the dimensions of the focal 
beam, resulted in the BBB opening volume reported herein37.  
 
Confocal image analysis 
The hippocampal formation was isolated from the surrounding brain tissue utilizing the merged-
channel images (composite), thus constructing a hippocampal mask. For individual biomarker 
analysis, the masked composite maximum intensity images were split into the constituent 
channels. Color-based segmentation by k-means clustering was applied in every channel to 
determine the sum of pixels belonging to the highest-intensities cluster that was then normalized 
by the sum of all pixels composing the hippocampal mask (Figure 23a). 
 
Additionally, a structural algorithm was developed to quantify the number of cells and the length 
of the processes affected by phosphorylated tau (Figure 23b). As previously described, the 
hippocampal mask was constructed and applied onto the red channel followed by color-based 
segmentation. The Hough transform was employed to detect circular objects and identify 
pathological cell centers. Residual noise was eliminated by singular value decomposition. 
Morphological operators enabling the connection of neighboring pixels and skeletonization, 
revealed the backbone of the processes along with branches and endpoints. The algorithm 
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used to initiate a stemming process search until an endpoint was reached. The distance of 
the endpoint to the cell center was measured. (b) The intensity algorithm utilized the 
composite image as input to generate a hippocampal mask, omitting the irrelevant 
neighboring structures. The mask was applied to all three channels separately followed by 
color-based segmentation via k means clustering. For every channel the density is reported 
as the ratio of the pixels belonging to the cluster with the highest value over the pixels 
constituting the entire hippocampal mask. Scale bar, 100μm. 
To report the difference in pyramidal processes length between groups, a Monte Carlo simulation 
was performed. The simulation constructs the probability density function (PDF) for the 
processes length of each hemisphere (sham contra, sham ipsi, sonic contra and sonic ipsi) 
followed by random sampling from each PDF and pairwise subtraction of the random samples223. 
The subtraction is demonstrated as the cumulative density distribution revealing the percent of 
length difference.  
 
Both the intensity- and structural- algorithms as well as the Monte Carlo simulation were 
evaluated in terms of accuracy by comparing the pathology of rTg4510 mice at different ages. As 
the disease progresses, the cells affected by the pathology should significantly increase as 
phosphorylated tau spreads from the processes that become shorter9,224. Pathological 
deterioration is also reflected by increased activity of immune cells (microglia and/or 
macrophages) evident by elevated CD68-positivity225. Increased cell population and CD68-
positivity accompanied by decreased length of the processes affected by phosphorylated tau was 
indeed detected in the older mice with the associated changes in intensity63.  
 
To estimate the statistical dependence between p-tau and microglia, and report on their 
colocalization probability, standard methods were employed; i. the Pearson’s correlation 
coefficient (PCC) and ii. Manders’ overlap coefficients; M1 and M2, where the threshold was set 




The equations describing the coefficients were implemented in MATLAB. Following the 
isolation of the CA1 sector from the surrounding tissue, the dependency coefficients were 
calculated using the raw intensities as inputs. Pixels outside the region of interest were assigned 




All values are expressed as means ± standard error of the mean (SEM). Differences between the 
means of the sham and treated groups as well as the ipsilateral and contralateral to the sonication 
sides were analyzed using 2-way repeated measures ANOVA. Statistical analysis was performed 
on the mean value obtained per animal; however, all samples (2-3 slices per mouse brain) are 
presented in the bar plots included in the study. Longitudinal analysis of the BBB opening 
volume and differences in the means distributed over the hippocampal subfields were analyzed 
with multiple Student’s t tests. The P values in both analyses were adjusted based on the Holm 
Sidak post hoc correction. All statistical analyses were performed using Prism 8 (Graphpad 
Software, San Diego, CA, USA) and the null hypothesis was rejected at the 0.05 level. 
Throughout the manuscript the “F” value in respect to the associated degrees of freedom is 
provided with the P value adjusted to the corrected multiple t-tests. The significance levels 




5.1.4 Results and Discussion  
Confirmation of the BBB opening and volume assessment was performed prior to the 
immunohistochemical analysis to evaluate potential differences in the opening volume. 
Representative coronal planes of the BBB opening at Bregma -2.70 ± 0.56 are shown in Figure 
24 for each group per week of sonication. Quantification of the opening volume (transgenic; 
wild-type, week 1: 54.8 ± 0.9 mm3; 52.83 ± 3.9 mm3, week 2: 52.46 ± 2.9 mm3; 54.98 ± 2.6 
mm3, week 3: 54.22 ± 3.3 mm3; 55.48 ± 1.6 mm3, week 4: 52.5 ± 2.5 mm3; 54.49 ± 4.3 mm3) did 
not reveal any significant differences in the opening size across weeks suggesting that repeated 
ultrasound application did not compromise the integrity of the barrier at least at this age (3.5-4.5 
months old). Moreover, the comparable BBB opening volumes of transgenic to wild-type 
animals indicated a  
similar response of the BBB to the ultrasound without evidence of edematous incidences as 
indicated by the T2-weighted images.  
 
FUS applied within the safety regime has been proven beneficial62,76,220 while vascular 
incidences have been reported in sonication protocols involving overlapping regions and 
repeated applications53. Despite operating in a safe ultrasound parametric space evaluated in 
previous studies76,112, we were interested in determining any potential effects of the technique on 
the neuronal integrity. Therefore, two slices per transgenic brain were counterstained for 
neuronal cells with the anti-NeuN (neuron-specific nuclear protein) and anti-β-tubulin ΙΙΙ 
antibodies (neuron-specific microtubule element) along with brain slices from a wild-type mouse 
to assess the sensitivity of the biomarkers. Neuronal compromise was qualitatively evident when 
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Quantification of the two channels separately based on their intensity normalized by their 
background (Figure 23a) showed that neither neuronal cells nor processes differed between the 
sonicated and sham brains (Figure 25). The neuronal cell density was 39.18 ± 1.41% and 36.46 ± 
1.25%, for the sham contralateral and ipsilateral side while 37.87 ± 1.3% and 39.18 ± 1.29% for 
the corresponding sides of the sonicated brains. Respectively, the neuronal processes density was 
39.31 ± 0.63% and 39.43 ± 0.97% for the sham contralateral and ipsilateral side while 38.25 ±  
0.67% and 39.56 ± 1.04% for the corresponding sides of the sonicated brains. These observations 
suggest that the ultrasound parameters applied in this study did not negatively impact the 
neuronal integrity at least to the sensitivity level of our detection. 
 
Establishing the neuronal integrity, we were then interested to investigate the response of 
phosphorylated tau protein to the application of ultrasound and the BBB opening. Frozen floating 
tissue was processed for immunohistochemistry by incubation with antibodies against 
phosphorylated tau and immune cell reactivity using AT8 (a monoclonal antibody recognizing 
AD-related phosphorylation at Ser202/Thr205 on human tau protein) and CD68 (monoclonal 
antibody binding to the corresponding lysosomal receptor of macrophages) respectively. 
Confocal microscopy enabled visualization of the p-tau spatial profile as well as correlation with 
the immune response. The distribution of phosphorylated tau changes with disease stage with p-
tau being present in the processes at early stages, but more pronounced in the somatodendritic 
compartment as the disease worsens9. Quantification of p-tau signal-intensity showed a 
significant reduction in the hemisphere treated with ultrasound (Figure 26b-c). In particular, we 
observed a reduction in the p-tau signal to the order of 57.35% (F[1,8] = 34.32;P=0.0004) when 
 comparing the contralateral hemispheres o
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Figure 23: The timeline of the experimental procedure is shown at the top. Briefly, five 
mice of the rTg4510 line at 3.5 months of age were recruited for four sonications, once per 
week and were sacrificed a day after the last treatment. MRI was performed after each 
sonication to confirm targeting accuracy and successful opening. Two slices per transgenic 
brain were counterstained for neuronal cells with the anti-NeuN and anti-β-tubulin ΙΙΙ 
antibodies along with brain slices from a wild-type mouse to assess neuronal integrity. 
Neuronal compromise could be qualitatively observed in transgenic animals compared to 
healthy mice by the decrease in the NeuN signal and the non-uniform signal emitted by the 
neuronal processes. However, no significant differences emerged from the application of 
ultrasound as shown by the quantitative measures. The mean (± standard deviation) 
neuronal cell density was 39.18 ± 4.25 % and 36.46 ± 3.77%, for the sham contralateral and 
ipsilateral side while 37.87 ± 4.14% and 39.18 ± 4.09% for the corresponding sides of the 
sonicated brains. Respectively, the mean value (± standard deviation) for the neuronal 
processes density was 39.31 ± 1.91% and 39.43 ± 2.93% for the sham contralateral and 
ipsilateral side while 38.25 ± 2.13% and 39.56 ± 3.3% for the corresponding sides of the 
sonicated brains. Scale bar, 100μm. 
(F[1,8] = 34.32;P<0.0001) when comparing the ipsilateral hemispheres (Figure 26c). However, 
the total p-tau cell numbers detected by the algorithm did not differ among the groups or the 
hemispheres as shown in Figure 26d. 
 
BBB opening induced by FUS has been shown to trigger an immune response determined by the 
energy deposited and the selected ultrasound parameters51. Under the current sonication regime, 
microglia activation was expected as the brain-residing myeloid cells reach for the sites of BBB 
leakage51,62. Microglia are inherently activated by the pathology225, however, the binding ligand 
that induces the conformational changes governs their performance in the brain83,84. 
Additionally, brain trafficking of peripheral immune cells has been associated with mitigation of 
neurological diseases attributed to their strong phagocytic capacitance227. However, peripheral 
immune cells are restrained from entering the brain, yet FUS has been shown to facilitate their 
infiltration by transiently disrupting the BBB51,53,222.  In this study, significant activation of 
immune cells on the order of 54.41% (F[1,8] = 46.4;P<0.0001) and 41.6% (F[1,8] = 
 46.4;P=0.0064) was observed in the hemisp
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Figure 24: The timeline of the experimental procedure. For this immunohistochemical 
analysis brain slices from the transgenic animals were counterstained for phosphorylated 
tau with the AT8 antibody and immune cell activation with the CD68 antibody while 
imaged by confocal microscopy. (b) Representative composite images of the sham and 
sonicated ipsilateral hemispheres are shown with the red channel corresponding to the 
signal emitted from phosphorylated tau, the green channel reflecting the immune response 
and the blue channel representing the cell-dye Hoechst 33342. (c) Bar scatter plot 
representation of the samples showing a significant reduction in the p-tau signal when 
comparing the hemispheres of the sham and the sonicated brain. In particular, we 
observed a reduction in the p-tau signal on the order of 57.35% (F[1,8] = 34.32;P=0.0004) 
when comparing the contralateral hemispheres of the sham and the sonicated brains, while 
72.65% (F[1,8] = 34.32;P<0.0001) when comparing the ipsilateral hemispheres. (d) On the 
other hand, the total cell numbers detected by the algorithm did not differ among the 
groups or the hemispheres (e) Immune cell activation was confirmed by the signal obtained 
from the CD68 marker. Immune system upregulation was expected due to pathology but a 
54.41% increase (F[1,8] = 46.4;P<0.0001) was observed in the hemisphere treated with 
ultrasound while a 41.6% (F[1,8] = 46.4;P=0.0064) increase in its contralateral side 
compared to the control brains. (f) Regression analysis between the p-tau signal and the 
immune cell activation yielded a significant deviation of the slope from the zero value 
suggesting a correlation between the two parameters (r2=0.3285; β=-2.136; P<0.0001). 
Scale bar, 100μm. 
side compared to the untreated brains (Figure 26e). Moreover, regression analysis between 
immune cells and p-tau signal revealed a negative correlation showing increased immune 
response in the brains with reduced phosphorylated tau presence (Figure 26f). Despite the 
relatively low correlation coefficient (r2=0.3285), the slope of the regression significantly 
deviated from zero (β=-2.136; P<0.0001) indicating that the two variables vary together in the 
opposite direction.  
 
Upon observation of the reduction in phosphorylated tau signal emitted from the sonicated 
hippocampus, further investigation of its spatial distribution along the pyramidal neuron was 
necessary. Given the CA1 being the hippocampal sector most affected by the pathology at this 
age in the rTg4510 model224 further quantification of the processes length affected by p-tau 
followed. In Figure 27a, it is qualitatively shown by the red channel that p-tau affects the 
neuronal processes along their in-plane length (longer p-tau processes) while application of 
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ultrasound decreases the neuronal processes depletion (shorter p-tau processes). Quantification 
of the p-tau processes length was performed by a custom algorithm that beginning from the cell 
soma tracked the pathological marker along the axon and returned its length (Figure 23b). In 
Figure 27b the cumulative density function (CDF) demonstrates the p-tau processes length across 
the four groups (sham contra, sham ipsi, sonic contra and sonic ipsi). The 95th percentile, 
denoted by the upper red line, crosses the CDF of the sonicated ipsilateral side at 300 μm (dotted 
red line), while at 700 μm (dotted red line) for the untreated brain. This finding suggests that the 
probability of finding a p-tau neuronal process equal or smaller than 300 μm in the sonicated 
brain and 700 μm in the unsonicated brain is 0.95. Despite establishing the high probability of 
finding shorter p-tau processes in the sonicated brain, to report on the differences in the p-tau 
processes length between the groups, a Monte Carlo simulation was designed223. The probability 
density function of the p-tau processes was constructed for the four groups. Samples from the 
distributions were randomly drawn, subtracted from each other pairwise and the cumulative 
density function of the resulting differences in length is reported herein228,229. The CDF of the 
length difference in p-tau processes between the sham and sonicated hemispheres is shown in 
Figure 27c. The probability of the p-tau processes having the same length is 0.32 (zero crossing) 
suggesting that 68% of the p-tau processes in the untreated brains are longer than the sonicated 
ones. Another observation that could be extracted from this figure is that the probability of a p-
tau process in the untreated brain being up to 600 μm longer than the sonicated brain is 0.94. 
Similar observations can be respectively drawn for the remaining groups. The accuracy of this 
method in the current application was evaluated by performing the equivalent analysis in the 





































































Figure 25: (a) Phosphorylated tau signal emitted from the affected pyramidal neurons of 
the ipsilateral and contralateral side in the CA1 sector of the sham and sonicated brains. 
(b) Comparison of the cumulative density function (CDF) of the p-tau processes length as 
obtained from each group (sham contra, sham ipsi, sonic contra and sonic ipsi). This graph 
describes the probability (y-axis) of finding p-tau processes of a certain or smaller length 
(x-axis). The 95th percentile (upper red line) crosses the CDF of the sonicated ipsilateral 
side at 300μm (dotted red line), while at 700μm (dotted red line) for the untreated brain. 
This finding suggests that the probability of finding a p-tau neuronal process equal or 
smaller than 300 μm in the sonicated brain and 700μm in the unsonicated brain is 0.95. (c) 
The cumulative density function of the difference in p-tau processes length between the 
sham and sonicated hemisphere (ipsi sham-ipsi sonic). The zero crossing denote the 
probability of p-tau processes having the same length between the two hemispheres. From 
this CDF it can be observed that 68% of the neurons on the sham ipsilateral side are longer 
than those on the sonicated ipsilateral side. Scale bar, 100μm. 
Since channel overlap in one plane does not suffice to justify biomarker colocalization, we 
investigated the orthogonal views12 of all microglia cells captured within the images and 
representative magnified examples (60x objective magnified by a factor of three) are shown in 
Figures 28a-d. Qualitative evaluation of the channel overlap revealed that microglia verge on the 
p-tau processes and follow morphologically their structure in the sham brains without, though, 
engulfing them, as shown in Figures 6a,c. However, following the application of ultrasound, 
fragments of p-tau can be found within the microglia in both hemispheres of the sonicated brains 
(Figure 28b,d) as suggested by the channel overlap in all three planes). Quantitatively, Figures 
28e-h include representative composite images from the CA1 region of each group with the 
corresponding monochromatic channels, where the green corresponds to the Iba1 biomarker and 
the red to the p-tau pathology. Each scatterplot shows the distribution of the pixels in the green-
red coordinate system providing information on the covariance of the markers. The scatterplot 
colormap indicates the pixel density. Figures 28e and 28g demonstrate the spatial distribution of 
the microglia and p-tau pathology in the sham brain with a PCC of 0.0345 for the ipsilateral side 
and 0.0495 for the contralateral side. The slope of the linear regression line between the two 
channels is 0.0273 for the ipsilateral and 0.0386 for the contralateral sham hemisphere. These 
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findings suggest a positive covariance of the two channels while the small value of the slope 
suggests that for high red channel intensities the green channel values remain small. In Figures 6f 
and 6h, representative examples of the sonicated brain are shown with a PCC of 0.068 for the 
ipsilateral and 0.0583 for the contralateral hemisphere with the corresponding slopes on the order 
of 0.207 and 0.122 respectively. The increase in the slope could be attributed to the reduced 
signal intensity in the red channel accompanied by the increase in green channel intensity while 
the PCC values were found comparable between groups. As particularly shown in the Figures 
28f and 28h scatterplots, the majority of the pixels spreads towards the higher values of the green 
channel while maintaining a relatively low value in the red channel. This finding suggests a 
decrease in the signal emitted from phosphorylated tau accompanied by an increase in the 
immune response as previously shown in Figure 26e. Cumulative results from all animals show 
comparable PCC values (Figure 28i) accompanied by a significant increase in the scatterplot 
slope on the order of 43% (F[1.6]=6.214;P=0.047) for the ipsilateral hemispheres along with a 
26.7% increase, albeit not significant, for the contralateral hemispheres after the application of 
ultrasound (Figure 28j). Furthermore, the percent of red-to-green channel contribution, measured 
here by Manders’ M1 overlap coefficient, significantly increased by 43% 
(F[1.6]=162.5;P<0.0001) for the ipsilateral hemisphere following FUS while the M2 coefficient 
decreased significantly (F[1.6]=258.9;P<0.0001) by 36.0% suggesting greater overlap between 
the green and the red channel. Similar findings were observed on the contralateral hemispheres 
with a 42.6% increase in the M1 coefficient and a 31.7 decrease in the M2 coefficient. The 






Figure 26: Microglia colocalization with phosphorylated tau protein. For this 
immunohistochemical analysis, two brain slices from the transgenic animals were 
counterstained for phosphorylated tau and microglia presence with the AT8 (red) and the 
Iba1 (green) antibody. Three Z-stack series were captured on a 60x objective covering the 
CA1 region. (a-d) Qualitative evaluation of the biomarker colocalization. The three planes, 
XY (main), XZ and YZ (orthogonal) are presented for a microglia cell. The images are 
magnified versions of the 60x objective and the corresponding video included in the 
Supplementary Material. (a, c) The microglia are shown to verge on the phosphorylated 
tau but not engulf it as indicated by the lack of the channel overlap in all three planes. (b, 
d) The microglia seem to engulf fragments of phosphorylated tau after the application of 
ultrasound in both hemispheres of the sonicated brains. The overlap of the two channels is 
consistent in all three planes. (e-h) The four panels follow the same structure: a composite 
image showing the merged and monochromatic images of the isolated CA1 sector and the 
scatterplot of the two channels. The scatterplot colormap indicates the pixels density. (e) 
The neuronal processes are largely affected by phosphorylated tau while the presence of 
microglia is evident in the ipsilateral sham hemisphere. The scatterplot has a slope (the 
slope obtained by performing linear regression between the two channels) of 0.022 
suggesting that more pathological tau is present (higher red channel values) than microglia 
(smaller green channel values) while Pearson’s correlation coefficient (PCC) is 0.0345 
suggesting minor statistical dependence between the biomarkers. (f) The sonicated 
hemisphere experienced a reduction in phosphorylated tau and an increase in microglia 
presence indicated by the higher value of the fitted slope equal to 0.207, while the PCC 
increased for this case to 0.068. (g) Similar findings to the ipsilateral hemisphere can be 
extracted from the contralateral sides where the slope is 0.038 and the PCC of 0.058 in the 
sham brain while (h) the slope reached 0.122 and the PCC 0.0.068 in the sonicated brain. (i-
l) Cumulative results on the dependency metrics. Comparable PCC values suggest that 
ultrasound did not affect the covariance of the two biomarkers. However, a significant 
increase in the slope of the linear regression line by 43% can be observed between the 
ipsilateral hemispheres (F[1.6]=6.214;P=0.047). Furthermore, the percent of red-to-green 
channel contribution, measured here my Manders’ M1 overlap coefficient, increased 
significantly by 43% (F[1.6]=162.5;P<0.0001) while the M2 coefficient decreased 
significantly by 36% (F[1.6]=258.9;P<0.0001) suggesting greater overlap of the green with 
the red channel in the ipsilateral hemisphere. Similarly, M1 overlap coefficient increased 
by 42.6% and M2 coefficient decreased by 31.7% in the contralateral hemispheres. Scale 
bar, 10μm. 
Overall we show that the complementary hallmark of the pathology, phosphorylated human tau 
protein, could be mitigated by the ultrasound-triggered upregulation of the immune system. In 
addition to the overall reduction in p-tau from the hippocampal formation, the spatial distribution  
 
of the pathological marker, primarily in the CA1 region, changed after the application of 
ultrasound (Figures 26-28). Monte Carlo simulations confirmed the reduction in phosphorylated 
111 
 
tau from the pyramidal processes as their length decreased significantly with the application of 
ultrasound (Figure 27). Ultimately, ultrasound was considered to have attenuated the 
pathological progression that is associated with a significant increase of p-tau in neuronal cells.  
 
Finally, the structural quantification showed that the contralateral neuronal processes were only 
150 μm longer than the ipsilateral in the sonicated brain at the 95th percentile (Figure 27b). The  
significant presence of immune cells and their colocalization with p-tau protein in the 
contralateral- 
to-ultrasound hemisphere could be driven by the migration of the resident microglia from the 
sonicated hemisphere to the contralateral side through the integrating tract78 and/or the 
infiltration of peripheral cells51,53,222.  
 
5.1.5 Limitations and Conclusions  
This study demonstrates the initial findings in bilateral reduction of phosphorylated tau in 
response to unilateral sonication due to the upregulation of the immune response in the rTg4510 
mouse model without accompanied compromise of the neuronal integrity, findings that are in 
agreement with recent observations from alternative tau models64. The p-tau reduction from the 
hippocampus could relate to deceleration of p-tau spreading or p-tau clearance from the brain. 
However, to assess the brain load in pathological proteins analytical techniques are needed. 
Moreover, whether the decrease in p-tau is functionally translatable in terms of memory 




The link between microgliosis and tau pathology is still debated in the existent literature79,82. 
Stimulus-dependent conformational changes and dystrophy have been associated with tau 
pathology while re-programming of the microglia to healthier phenotypes has recently emerged 
as a therapeutic strategy83,84. The beneficial effects of microglia on Aβ pathology have been 
supported by studies showing clearance of the plaques after FUS-induced BBB opening61,62 and 
this seems to be the same for tau pathology as well64. Moreover, infiltration of peripheral 
macrophages has been emerged as a potential candidate for the amelioration of Alzheimer’s 
disease227,230. However, the primary challenge in those studies remains the limited brain 
infiltration due to the barrier, an obstacle that FUS has been shown to overcome222. Distinction 
between microglia and peripheral immune cells including macrophages and monocytes was not 
attempted in the present study given that the employed antibodies (CD68 and Iba1) are not 
adequate markers of unique microglia signature225,231. Therefore, the immune response observed 
in Figure 26 could be attributed to their synergistic action. The increase in immune cell 
activation was also accompanied by a reduction in the phosphorylated tau protein in the brains 
examined (Figure 26e-f). These findings were confirmed by the significant increase in the fitted 
slope (Figure 28e-i) suggesting a decrease in phosphorylated tau (red channel intensity) and an 
increase in microgliosis (green channel intensity). In addition, similar observations could be 
drawn from analyzing Manders’ overlap coefficients, since they describe the fraction of one 
channel in compartments of the second channel232. Along these lines, significantly increased M1 
and decreased M2 indicate that the majority of the phosphorylated tau protein could be found in 
compartments associated with microglia following the application of ultrasound (Figure 28k,l). 
Although this finding could also be explained by the reduction in p-tau accompanied by the 
upregulated immune response (Figure 26e), single-cell, three-dimensional qualitative evaluation 
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of the channel overlap strengthens the argument that microglia could engulf the pathological tau 
(Figure 28a-d) following sonication. Whether FUS-induced BBB opening drives a “healthy” 
activation of microglia or infiltrating immune cells82 help reduce p-tau, remains unclear but these 
mechanisms could explain the positive effect established herein.  
 
5.2 Focused ultrasound-induced blood-brain barrier opening initiates pathological changes 
in the 3xTg-Alzheimer’s mouse model.  
5.2.1 Abstract  
Focused ultrasound (FUS) has been proven to reduce amyloid plaques and hyperphosphorylated 
tau protein from the hippocampal formation and the entorhinal cortex in different mouse models 
of Alzheimer’s disease (AD). Given the beneficial effects of FUS on isolated AD pathologies, 
we investigated its functional and morphological outcomes on brains bearing both pathologies 
simultaneously. Eleven transgenic mice of the 3xTg-AD line (14 months old) and eleven age-
matched wild-type animals received bilateral sonications covering the hippocampus once per 
week for four consecutive weeks. Following the last treatment, sonicated animals and control 
littermates underwent behavioral testing in the Morris water maze (MWM). All mice received a 
5-day training familiarizing with reaching the escape-platform within 60 seconds. Following the 
training, the platform was removed and the amount of time spent in each MWM quadrant was 
quantified. The following week all animals were sacrificed and their brains processed for 
immunohistochemistry and biochemical analysis. Animals that received FUS spent significantly 
more time in the quadrant where the platform was located while this functional improvement 
correlated well with a 58.31% decrease in the neuronal length affected by tau confirmed by a 
27.2% reduction in tau levels shown by immunoblotting. Amyloid plaque population, volume 
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and overall load were also decreased yet not significantly. For the first time, bilateral sonication 
significantly ameliorated the pathology and improved the spatial memory of transgenic animals 
with complex AD phenotype.  
 
5.2.2 Introduction 
Alzheimer’s disease is a chronic and progressive neurodegenerative disorder resulting in a 
demented elderly population233. The AD defining features include the accumulation of amyloid-β 
plaques and intraneuronal neurofibrillary tangles, associated with gradual cognitive decline13. As 
of February 12, 2019, 28 out of 132 clinical trials administering pharmacological agents reached 
phase III stage, 11 investigating symptomatic agents-3 cognitive enhancers and 8 alleviating 
behavioral symptoms-and 17 disease modifying drugs-6 biological therapies and 11 small 
molecules. From the disease modifying therapeutic strategies, 10 are primarily, if not 
exclusively, targeting amyloid-β, one tau pathology and the rest are neuroprotective, anti-
inflammatory or metabolic approaches234.  
 
Ultrasound-facilitated BBB opening has been evaluated in a battery of clinical trials recruiting 
initially Glioblastoma multiforme (GBM) patients235. The completion of the trial revealed an 
increase in the median progression-free survival in the 19 enrolled patients, who received 
repeated treatments prior to systemic administration of carboplatin235. These beneficial outcomes 
paved the way for the expansion of clinical research utilizing ultrasound leading, eventually, to 
the first clinical trial revealing a safe and reversible BBB opening in 5 AD patients using MR-
guided ExAblate system developed by Insightec (Insightec Inc., Tirat Carmel, Israel)116. 
Although a secondary outcome measure, researchers evaluated the amyloid load in the patients’ 
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brains prior to and following the sonication without detectable changes. Providing the initial 
feasibility of the study, a phase IIa clinical trial was designed and is currently enrolling AD 
patients who will be repeatedly sonicated for three times in total (NCT03739905). Another 
clinical trial (NCT03671889) employing a similar MR-guided system is actively selecting AD 
patients to be embedded in a study with safety and efficacy as the primary outcome measures. 
Recently, our in-house developed clinical system for neuronavigation-guided FUS-induced BBB 
opening outside the magnetic bore was approved to treat 6 AD patients including assessment of 
pathological alteration following the procedure (NCT04118764)186.  
 
The ultimate aim of the clinical research in sonicating AD patients without delivering a 
pharmacological agent lies in the replication of the promising pre-clinical data that indicate 
pathological amelioration accompanied by functional improvement62,236. Briefly, it was proven 
over the past decade that amyloid plaques can be reduced following repeated ultrasound targeted 
in one region or swept across the brain62,236. One prominent mechanism for the amyloid 
clearance from the brain is the FUS-triggered immune response, since microglia have been found 
to engulf the amyloid plaques following sonication61,62. Moreover, a time course study 
investigating the effect and persistence of a single sonication in amyloid plaques, concluded that 
the plaques shrank in more than half their initial volume, the days following sonication and the 
effect persisted for two weeks237. Therefore, repeated biweekly sonications were evaluated and 
indicated a plaque population reduction on the order of 27% accompanied by a 40% decrease in 




Preclinical findings targeting amelioration of tau pathology by FUS-induced BBB opening have 
been recently emerged. The studies conducted so far, though employing different transgenic 
animal models overexpressing mutant human tau, converge on their primary findings that 
phosphorylated tau can be eliminated from the brain following repeated sonications63–65,220. 
Immune response to the sonication and autophagy have been proposed as potential mechanisms 
of tau clearance63,65.  
 
Despite the promising preclinical evidence, a common limitation in these studies is the 
expression of a single pathology in the animal models employed. Animals would overexpress 
proteins linked to familial AD (FAD), mutant amyloid precursor protein (APP), or APP and 
presenilin (PS) resulting in the formation of amyloid plaques238. Alternatively, rodents would 
overexpress a mutation (P301L or K369I) in the microtubule-associated protein tau (MAPT) 
resulting in destabilization of the microtubule network and tauopathies63–65,220. However, these 
models fall short in resembling AD that is defined by the presence and interplay of both amyloid 
plaques and neurofibrillary tangle pathology. Therefore, the beneficial outcomes and the 
proposed mechanisms of these studies need to be evaluated in animal models with concurrent 
pathology.  
 
We examine herein whether Alzheimer’s pathology can be attenuated by ultrasound to (i) 
investigate the efficacy of repeated bilateral FUS for the reduction of human total tau and 
amyloid plaques from the 3xTg-AD mice that display both plaque and tangle pathology in the 
hippocampus and (ii) establish the functional imprint of the pathological amelioration attributed 




5.2.3 Materials and Methods  
In vivo experiments 
For this study, 22 female mice of the 3xTg-AD line were employed, at the age of 14 months. 
This widely used strain contains three mutations associated with familial Alzheimer's disease 
(APP Swedish, MAPT P301L, and PSEN1 M146V) and expresses a progressive development of 
both plaques and tangles243. Age- and gender-matched non-transgenic animals were included in 
the study as well, while all animals were randomly assigned to the sham and sonicated groups 
(eleven mice per group). Animals were group-housed under standard conditions (12 hr light/dark 
cycles, 22oC), were provided with a standard rodent chow (3 kcal/g; Harlan Laboratories, 
Indianapolis, IN, USA) and water ad libitum. All procedures involving animals were approved 
by the Columbia University Institutional Animal Care and Use Committee. 
 
The animals involved herein (sham and sonicated) were anesthetized with a mixture of oxygen 
and 1-2% isoflurane (SurgiVet, Smiths Medical PM, Inc.,WI), placed prone with the head 
immobilized by a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA) and depilated to 
expose the suture anatomy and minimize acoustic impedance mismatch. Identification of the 
parietal and interparietal bone intersection enabled proper positioning of the transducer following 
a grid-guided targeting procedure27. Targeting the hippocampal formation involved positioning 
of the transducer 3 mm anteriorly to the lambdoid suture, and 1.5 mm laterally to cover the 
dorsal part, while 2 mm anteriorly and 3.2 mm laterally for the ventral part. Both hemispheres 




The mice included in the sonication groups (transgenic and non-transgenic) received ultrasound 
in a cavitation-controlled regime (Ji, R.et al. in preparation) with a pulse length of 10 ms and a 
repetition frequency of 5 Hz at PNP of 0.40 MPa after accounting for 18% murine skull 
attenuation. Acoustic emissions were monitored in real time to assess the degree of cavitation 
and animals were injected with microbubbles until the cumulative cavitation dose reached a pre-
set level associated with a single BBB opening on the order of 31.3 ± 16 mm3 (Ji, R.et al. in 
preparation). Thus, to accommodate for a constant cavitation level, the microbubble 
administration during the sonication ranged between 4-6 intravenous injections of  polydisperse 
in-house manufactured29,199 microbubbles diluted in saline (0.1 μl/g, mean diameter: 1.4 μm), 
while the duration of a single sonication varied from 8 to 360 sec. Reinjections were 
administered when the cavitation levels dropped below 1 dB, relative to the baseline cavitation 
levels when no microbubbles were present. The sham groups were subjected to the same 
procedure without triggering the transducer, received the average microbubble injections, as 
established by the sonicated group,s and remained under anesthesia the average sonication 
duration. All animals underwent magnetic resonance imaging for BBB opening confirmation and 
safety assessment. This procedure was repeated once per week for four consecutive weeks. 
Following the last sonication, all animals were transferred to the behavioral facility to acclimate 
for five days prior to behavioral testing. Behavioral testing using the MWM followed and lasted 
for five consecutive days. After the last day of behavioral testing, which was approximately three 
weeks after the last sonication, the mice were sacrificed  at the age of 15-16 months. 
 
Focused ultrasound  
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Similar to the previous section (section 5.1.3), the sonications were carried out by a single-
element, spherical-segment FUS transducer operating at 1.5 MHz, driven by a function generator 
(Agilent, Palo Alto, CA, USA) through a 50-dB power amplifier (E&I, Rochester, NY, USA). 
The central void of the therapeutic transducer held a pulse-echo ultrasound transducer (center 
frequency: 10 MHz, focal depth: 60mm, radius 11.2 mm; Olympus NDT, Waltham, MA) used 
for alignment, with their two foci coaxially aligned. The imaging transducer was driven by a 
pulser-receiver (Olympus, Waltham, MA, USA) connected to a digitizer (Gage Applied 
Technologies, Inc., Lachine, QC, Canada). A cone filled with degassed, distilled water was 
mounted onto the transducer assembly. The transducers were attached to a computer-controlled 
3D positioning system (Velmex Inc., Lachine, QC, Canada).  
 
Magnetic resonance imaging 
As per section 5.1.3, all animals underwent magnetic resonance scanning with the 9.4T MRI 
system (Bruker Medical, Boston, MA) following the sonication procedure. The mice were placed 
in a birdcage coil (diameter 35 mm), while being anesthetized with 1 – 2% isoflurane and 
respiration rate was monitored throughout the imaging sessions. MR images were acquired using 
a contrast-enhanced T1-weighted 2D FLASH sequence, 30 minutes following the intraperitoneal 
bolus injection of 0.3 ml gadodiamide (GD-DTPA) (Omniscan, GE Healthcare, Princeton, NJ) 
while T2-weighted MRI was performed one day after the sonication to detect any potential 
damage using a  2D RARE sequence94. 
 
Morris Water Maze (MWM) 
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In order to test spatial learning and short term memory, MWM was conducted, following the 
procedure previously described241. The test was carried out during the light cycle and in a 
circular pool of 120 cm in diameter, filled 45 cm with tap water. The water was opaque by the 
addition of nontoxic white paint (Crayola) and kept at room temperature throughout. The pool 
contained spatial cues placed along the wall, which were kept constant through all testing days 
(Figure 27A). The trials were recorded and analyzed using WaterMaze video tracking software 
(Actimetrics).  
 
The training was a five consecutive day acquisition period, made up of four trials per day. Each 
animal was assigned a specific target quadrant, consistent through all trials and days, which 
contained an escape platform. The platform was consistently kept 3 cm below the surface of the 
water, hidden from the animals during the test. The dropping-quadrant for each animal was 
alternated in a semi-random order and it would be either opposite or adjacent to the target 
quadrants; the assigned target quadrant was never selected as the dropping-quadrant (Figure 
27A). 
 
Each trial began when the animal was gently lowered into the water, facing the pool’s wall. Each 
animal was allowed to find the platform within 60 sec. If the animal did not reach the platform 
within the given timeframe, it was then guided and gently placed on the platform. The animal 
was allowed to remain on the platform for 15 sec before being removed. After each trial the 
animal was placed in a cage lined with absorbent material and allowed to rest for 60 sec under a 
heat lamp. On the fifth day a probe trial was carried out, which occurred 3 hours after the last 
training trial. The hidden platform was removed from the target quadrant during the probe trial 
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and the animal was lowered into the quadrant opposite to the target quadrant. It was given 60 sec 
of exploration time before being removed. This probe trial tests the acquisition of spatial learning 
and short term memory239–241,244. The behavioral measures that were recorded and analyzed were 
the latency to reach the platform, the distance traveled during the training trials and the time 
spent in every quadrant during the probe trial (Figure 27).   
 
Immunofluorescence  
Five animals per group (5/11) were transcardially perfused (30 mL PBS followed by 60 mL 4% 
paraformaldehyde) following the completion of behavioral testing. Similar to section 5.1.3, the 
brains were extracted, preserved in PFA for 24 h and then in 30% Sucrose for at least 2 days 
prior to freezing. After brains were frozen on dry ice, cryostat-cut coronal hippocampal sections 
(35 μm) were collected in anti-freezing solution. Then, at least 3 free-floating sections of the 
intermediate and caudal hippocampus with a 6-sections gap were processed for 
immunohistochemistry. Prior to staining brain sections were pre-treated with 70% Formic Acid 
for 3 minutes to expose the Aβ42 epitope. The sections were sequentially washed in 0.1M PBS, 
treated with 5% donkey serum in 0.3% PBST for thirty minutes with the addition of mouse 
seroblock (BUF041, Bio-Rad Laboratories) for the last ten minutes followed by overnight 
incubation at 4°C with the primary antibodies: i. mouse anti-human-tau (HT7, 1:500, (HT7, 
1:500, MN1000, Invitrogen) and rabbit anti-human-Aβ42 (1:500, AB5078P, EMD Millipore ) 
antibodies. Then, sections were washed in PBS and incubated for 60 min in 0.3% PBST with 5% 
donkey serum containing the respective donkey-raised secondary antibodies, Texas Red- 
(1:1000, SAB3701155, Sigma-Aldrich) and Alexa488-conjugated (1:1000, SAB4600036, 
Sigma-Aldrich).After the incubation, the sections were washed again in PBS and mounted on 
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slides. The slides were washed three times with 0.02% Tween20 in PBS and treated with 
Hoechst 33342 (5 μm/ml, H21492, Thermo Fisher) for ten minutes. Finally, the slides were 
washed with PBS and cover slipped with Fluoromount-G (00-4958-02, Thermo Fisher)  solution. 
 
The large field confocal images of the hippocampus were captured on a 20× objective of a Nikon 
confocal microscope (Nikon Instruments Inc., Melville, NY, USA) with the same exposure 
parameters for the lasers. Tile (mosaic) and a Z-stack (2 μm step, 7 series) were necessary were 
acquired and processed to produce the resulting maximum intensity image.  
 
Immunoassays 
Six animals per group (6/11) were sacrificed by cervical dislocation with their brains extracted 
and the hippocampus dissected on ice within a minute prior to storage at -80°C. Frozen 
hippocampi were weighted and homogenized without thawing in T-PER buffer (78510, Thermo 
Fisher) containing a protease and phosphatase inhibitor cocktail (78442, Thermo Fisher). The 
homogenate was then split into two parts and stored at -80°C until used for immunoblots and 
enzyme-linked immunosorbent assays (ELISA). 
 
The first part of the homogenates was centrifuged at 3,000 g for 10 min at 4°C and the 
supernatant was recovered. Proteins were run on 4-12% Bolt Bis-Tris precast gels 
(NW04120BOX, Invitrogen) using 1 × MES SDS running buffer (B000202, Invitrogen) and 
under reducing conditions (B0009, Invitrogen). Proteins were then transferred to nitrocellulose 
membranes (iBlot2, IB23001, Invitrogen) using iBlot™ 2 Gel transfer system (IB21001, 
Invitrogen). Blots were blocked for 60 min using 5% non-fat dry milk (Omniblok, Americanbio 
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Inc) in Tris-buffered saline with Tween-20 (TBST, 0.1M Tris, 0.15M NaCL and 0.1% Tween-
20). Blots were then incubated overnight at 4°C in 5% milk TBS-T with HT7 primary antibody 
(1:2000, MN1000, Invitrogen) and loading control GAPDH (1:20000, G8795, Sigma-Aldrich). 
The next day blots were washed with TBST and then incubated for 1 h at room temperature in 
5% milk TBST with HRP conjugated secondary antibody (1:100000, 115-035-003, Jackson 
ImmunoResearch Laboratories Inc.). Membranes were developed with enhanced 
chemiluminescent solution (SuperSignal™ West Pico Plus ECL, 34580, Thermo Scientific) and 
imaged using FluorChem imaging system (Alpha Innotech Corp). Protein band intensities were 
then quantified using ImageJ software (NIH, Bethesda, United States). The average intensity of 
the human total tau (HT7) band over the average intensity of the control band (GAPDH) of the 
immunoblot were quantified and the results are presented as the HT7/GAPDH ratio.  
 
The second part of the homogenates was ultracentrifuged at 100,000 g for 1 h at 4°C. 
Supernatant was then recovered and used to measure soluble Aβ-42 levels using ELISA. The 
measurements were carried out using the specific Human Aβ-42 kit (KHB3441, Invitrogen) 




The enhancement in the horizontal plane of the MR images was quantified by volumetric 
analysis encompassing the hippocampal formations in both hemispheres37. 3D images were 
normalized with the average reference-intensity obtained from the volume of an out-of-focus 
structure enhancing the contrast of the Gadolinium-diffuse area. Active contours were 
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employed245 to isolate the hyperintense area corresponding to the BBB openings on every slice 
throughout the entire brain by matching the number of slices to the size of the geometric beam 
according to the acquired resolution. The sum of the pixels enclosed within the contours yielded 
the area of the BBB opening while performing the analysis over 17 consecutive slices, resulted in 
the BBB opening volume reported herein37.  
 
Confocal image analysis 
The hippocampal formation was isolated from the surrounding brain tissue utilizing the merged-
channel images (composite), thus constructing a hippocampal mask. For individual biomarker 
analysis, the masked composite maximum intensity images were split into the constituent 
channels. Throughout the rest of this study, the red and green channels represent signal emitted 
from human total tau and Aβ42, respectively. 
 
The  structural algorithm previously developed and described in section 5.1.3 was employed 
herein to quantify the number of cells and the length of the processes affected by tau63. As 
previously described, the hippocampal mask was constructed and applied onto the red channel 
followed by k-means segmentation to isolate the highest intensities. The Hough transform 
enabled the detection of circular objects and the identification of the pathological cell centers. 
Morphological operators connected the neighboring pixels and skeletonization, revealed the 
backbone of the processes, the branches and the endpoints. Utilizing the cell center coordinates 
as the initial point, the algorithm followed the skeleton within a defined neighborhood until 
reaching all endpoints. The distance of every endpoint to the cell center was measured and the 




Estimation of the amyloid plaque volume and population resulting from image quantification 
was implemented by utilizing the green channel. The entire image was normalized by the 
average signal emitted from an out-of-focus region, thus enhancing the contrast of the plaques 
with the surrounding tissue, followed by binarization with a fixed threshold throughout the 
analysis. The boundaries of the plaques were automatically detected246, the area enclosed within 
each boundary measured and the volume inferred by the resolution and the in-plane radius of 
each plaque in MATLAB. The algorithm aside from the plaque volume yielded the location and 
the population per image. 
 
Statistical analysis 
All values are expressed as means ± standard error of the mean (SEM). Longitudinal analysis of 
the BBB opening volume was analyzed with multiple Student’s t tests. Differences between the 
means of the sham and treated groups were analyzed using Student’s t tests while 2-way repeated 
measures ANOVA was employed for the MWM analysis. Statistical analysis was performed on 
the mean value obtained per animal and the P values in the analyses were adjusted based on the 
Holm Sidak post hoc correction when necessary. All statistical analyses were performed using 
Prism 8 (Graphpad Software, San Diego, CA, USA) and the null hypothesis was rejected at the 
0.05 level. Throughout the manuscript the “F” value in respect to the associated degrees of 
freedom is provided with the P value adjusted to the corrected multiple t-tests. The significance 




5.2.4 Results and Discussion  
In this study, 44 animals (transgenic and non-transgenic) were included in total to assess 
pathological differences and functional outcomes attributed to the effect of pathological 
alteration and ultrasound application.  
 
The foremost important aspect of the study was the repeatability of the BBB opening and the 
bilateral targeting accuracy in this transgenic mouse model. Magnetic resonance imaging 
revealed consistency in the BBB opening among samples as well as longitudinally across weeks 
(Figure 28), similar to our previous study63 (section 5.1.4). Quantification of the BBB opening 
volume in the transgenic animals was measured on the order of 57.5 ± 8.3 mm3, 51.4 ± 12.5 
mm3, 51.00 ± 9.3 mm3 and 46.3 ± 14.2 mm3 for the four weeks respectively. Statistical analysis 
confirmed the lack of significant differences in the opening size across weeks, similar to our 
previous study247, deeming repeated ultrasound suitable for this transgenic mouse model at this 
age given the technique did not compromise the barrier or initiated any edematous incidences as 
indicated by the T2-weighted imaging. 
 
Consistency of the BBB opening location and magnitude was necessary to accurately assess 
behavioral changes associated with the learning rate and short-term spatial memory with 
contained variance. MWM has been established to detect cognitive changes related to learning 
and memory given the confinement of the amyloid aggregation and tangle accumulation in the 
hippocampus, cortex and amygdala, in this specific strain243. MWM examines the functionality 
 of the long- and short-term memory that sho
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Figure 27: Repeated sonications improve spatial memory in transgenic and non-transgenic 
mice: A. The schematic of the Morris Water Maze setup that was used to behaviorally 
examine the animals in respect to their spatial memory functionality. The circular maze is 
considered to consist of four quadrants, the target, the opposite and the adjacent. B. 
Learning curves of the escape latency and the distance traveled to find the hidden platform 
are presented herein and plotted against the days of training. Both the distance traveled 
(F[4,144] = 15.57; P < 0.0001) and the escape latency (F[3,36] = 7.542; P = 0.0005) 
significantly deteriorated for the sham transgenic animals the last day of the training while 
all other groups continued to improve. C. Representative individual heatmaps of the time 
spent in every quadrant followed by the cumulative results on the probe trial. The sham 
transgenic animals did not show preference over any quadrant while the sonicated 
transgenic animals spent significantly more time in the target quadrant (F[1.637, 16.37] = 
4.051; P = 0.044). Respectively the non-transgenic mice spent more time in the target 
quadrant with the sonicated group at a much higher percentage (sham non-transgenic: 
F[1.965, 17.68] = 6.375; P = 0.0085, sonicated non-transgenic F[1.776, 15.99] = 16.48; P = 
0.0002). 
since the impairment is evident from 6 months of age239,240. To investigate the effect of 
ultrasound in the cognitive changes detected, non-transgenic mice underwent the same task and 
three metrics were employed: the escape latency from the maze, the distance traveled from  the 
dropping point to the escape platform and the time spent in each quadrant following the platform 
removal (probe trial). Mice received four training trials per day for five consecutive days in the 
spatial version of the MWM shown in the schematic of Figure 27A.  For the distance traveled an 
effect was observed for both days (F[4,144] = 15.57; P < 0.0001) and groups (F[3,36] = 7.542; P 
= 0.0005) suggesting a differentiation in the learning pace (Figure 27B). The sonicated 
transgenic group reached the escape platform traveling similar distance to the non-transgenic 
groups (sham and sonicated) while the sham transgenic group traveled significantly more 
distance until reaching the platform. Equivalent results were obtained for the escape latency with 
an effect for days (F[4,144] = 35.71; P < 0.0001) but not for groups, indicative of learning 
improvement for all groups over the training days with similar learning rates (Figure 27B). 
Despite the comparable learning pace, the sham transgenic group significantly deteriorated on 
the fifth day needing more time to escape the maze, while the sonicated transgenic group 
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remained consistently fast at escaping, similar to the sham non-transgenic and sonicated non-
transgenic groups. Two hours after the training trial, a 60 sec probe trial was conducted during 
which the animals were allowed to spent time in the maze without a hidden platform and the 
time spent in the target, opposite and adjacent quadrants was measured244. Representative 
heatmaps from each group show the percent of time spent in the maze followed by the 
cumulative results (Figure 27C). The sonicated transgenic mice spent significantly more time in 
the target quadrant compared to the opposite (target:35.37%, opposite:18.30%, adjacent 
left:21.96%, adjacent right:24.37%; F[1.637, 16.37] = 4.051; P = 0.044), in contrast to the sham 
transgenic animals that spent comparable amount of time in every quadrant (target:31.01%, 
opposite:20.63%, adjacent left:21.52%, adjacent right:26.84%). The percent of time the sham 
non-transgenic animals spent in the target quadrant was found significantly higher than the 
opposite (target:37.77%, opposite:24.29%, adjacent left:17.04%, adjacent right:20.20%; F[1.965, 
17.68] = 6.375; P = 0.0085), while the sonicated non-transgenic group spent significantly more 
time in the target quadrant compared to all other quadrants (target:43.20%, opposite:17.80%, 
adjacent left:20.80%, adjacent right: 18.20%; F[1.776, 15.99] = 16.48; P = 0.0002). These data 
indicate that sonications rescued spatial memory deﬁcits in the transgenic animals while 
improved the short-term memory performance in non-transgenic mice as well.  
 
Given the beneficial effect of ultrasound on spatial memory established by the improved 
performance of the sonicated non-transgenic group it is unclear whether the improved 
functionality observed in the sonicated transgenic mice could be attributed to the ultrasound 
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decrease in the population and volume on the order of 41.14% (t[7]=1.968; P=0.08) and 
28.4% (t[7]=1.277; P=0.24), respectively, in the sonicated brains. Along the same lines, 
Αβ42 quantification with sandwich ELISA confirmed the decreasing trend following 
sonications by 9.33%, yet lacking significance (t[9]=0.851; P=0.41). Scale bar: 100μm. 
neither measure reached significance. Similarly, Αβ42 quantification with sandwich ELISA 
confirmed the decreasing trend following sonications by 9.33%, yet lacking significance 
(t[9]=0.851; P=0.41).  
 
Despite the behavioral improvement and its correlation to the volume of BBB opening, the 
amyloid load in the sonicated brains was not significantly reduced in the presence of tau 
pathology. To determine whether the beneficial effects of ultrasound in brains with isolated tau 
pathology observed in previous studies63,64 could be observed when amyloid concurrently 
develops in the hippocampus, we performed immunohistochemical analysis and immunoblotting. 
Evident from the confocal images is the reduction of human total tau (HT7) protein from the 
neuronal processes similar to our previous study63. Quantification of the processes’ length using 
the structural algorithm developed herein revealed a significant reduction of the neuronal length 
affected by tau on the order of 58.31% (t[6] = 2.802; P = 0.0311). Tau reduction from the 
hippocampus was confirmed by immunoblot analysis. Taking the ratio of the HT7 over the 
GAPDH average intensity-band showed a significant reduction in the brains treated with 
ultrasound compared to the sham group on the order of 27.33% (t[9] = 3.771; P = 0.004).  
 
Overall, we show that both hallmarks of the AD pathology, human amyloid-β42 and tau protein, 
could be mitigated by repeated ultrasound applications. In addition to the significant reduction in 
tau from the hippocampal formation, the spatial distribution of the pathological marker altered 
following the application of ultrasound. Neuronal processes were less affected by tau that was 
133 
 
significantly reduced from the brain evidenced by immunoblotting. Concurrent with the 
beneficial outcomes in tau distribution, the amyloid plaque population, volume and overall load 
were also decreased, yet the effect was less pronounced and therefore not significant. Ultimately, 
ultrasound is considered to have attenuated the pathological progression that resulted in 
functional improvement and especially in the enhancement of short-term spatial memory. 
However, it is still unclear whether the pathological amelioration or its synergy to the 
downstream effects following sonication are solely responsible for the behavioral outcomes. 
Significant improvement in the memory of non-transgenic animals after repeated sonications 
leaves room for further investigation of the effect ultrasound has on memory cells. Behavioral 
measures following ultrasound have been previously shown in alert and healthy non-human 
primates whose reaction time improved by 23 ms and touch error reduced by 0.76 mm while 
being sonicated60. It is the first time tau reduction has been reported and confirmed by both 
immunoblotting and immunohistochemical image analysis in brains that suffer from amyloid and 
tau pathology concurrently.  
 
5.2.5 Limitations and Conclusions  
This study investigates whether the initial findings of tau reduction in the rTg4510 mouse model 
that only expresses tau pathology could be replicated in the 3xTg-AD mouse model; in which 
amyloid-β and tau pathology concurrently affect the hippocampus. Pathological amelioration 
was confirmed by immunohistochemical analysis as well as immunoassays providing evidence 
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response was expected to have returned to normal51,53,221 by the time of sacrifice (2-3 weeks post 
the last sonication). Design of a following set of experiments with a different timeline could shed 
light on this hypothesis. Moreover, recent findings in the K3 mouse model overexpressing tau 
pathology that was repeatedly sonicated over the entire brain, pointed towards autophagy as a 
potential clearance mechanism ruling out ubiquitination of tau248. This path should be further 
explored for the 3xTg-AD mouse model as well.  
 
5.3 Contribution 
A few studies have explored the immunomodulatory effects of FUS-induced BBB opening alone 
in wild-type51,53,221 and transgenic mouse models62,64, characterized by extracellular 
proteinaceous inclusions.  
 
In the first part of this study, we showed that repeated applications of FUS-induced BBB opening 
in a transgenic mouse model of Alzheimer’s disease overexpressing tau pathology reduced 
phosphorylated tau from the hippocampus without compromising neuronal integrity. The 
pathological amelioration was found to be correlated with the induced immune response since 
microglia were observed to colocalize with phosphorylated tau. 
 
In the second part of this study, we showed that repeated applications of FUS-induced BBB 
opening in the 3xTg-AD mouse model of Alzheimer’s disease, that overexpresses amyloid-β and 
tau pathology concurrently, simultaneously reduced tau protein and decreased the amyloid-β 
load. The changes in the pathological protein profiling, along with the concurrent downstream 




The results of the studies described in this chapter have been published in peer reviewed 
scientific journals63. 
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Chapter 6: Conclusion and Future Work 
This dissertation entails the quantitative analysis of the focused ultrasound-induced blood-brain 
barrier opening with applications in neurodegenerative disorders. In summary, the technique was 
optimized in terms of targeting and BBB opening volume prediction that could be detected with 
magnetic resonance imaging in the absence of contrast agents. Along with the method 
improvement, drug delivery was attempted in rodents resulting in dopaminergic upregulation in 
Parkinsonian brains. Multiple administrations were shown to have similar outcome measures 
with single gene delivery. Finally, repeated sonications of two different Alzheimer’s mouse 
models revealed the beneficial immunomodulatory effects of FUS-induced BBB opening that 
reduced tau pathology in both models accompanied by functional improvement in the latter.  
 
Initially, the relationship between incidence angle and BBB opening volume was studied. The 
volume of opening normalized with the skull thickness was found to monotonically increase with 
both close-to-normal incidence angles and peak negative FUS pressure. Anatomically, 80.35% of 
the opening was found on gray matter regions compared to only 19.41% belonging to the white 
matter. The opening was found to be shifted axially towards the transducer by 2.36±1.74 mm and 
laterally by 1.18±1.05 mm. Following these results, the BBB opening volume could be predicted 
knowing the ultrasound trajectory and the associated skull thickness aside from the applied 
pressure. Moreover diffusion weighted imaging was developed to detect BBB opening sites 
revealing a preferred unidirectional flow pattern following the sonication. Fractional anisotropy 
increased by 82.6% while polar and azimuthal angles decreased by 35.6% and 82.4%, 
respectively. In conclusion, DTI was deemed a viable alternative to contrast-enhanced MR 




For the next part of this dissertation, we show that FUS-facilitated delivery of neurotrophic 
factors (either through protein or gene administration) over both the striatum and the ventral 
midbrain, ameliorates the damage to the nigrostriatal dopaminergic pathway in the sub-acute 
MPTP mouse model. Briefly, single NTN delivery resulted in the significant upregulation of the 
nigrostriatal pathway by 20% in the midbrain only, while multiple administrations significantly 
improved the dopaminergic activity by 22% in the midbrain and 50% in the striatum. Similar 
findings were shown for the AAV-GDNF delivery that increased TH immunoreactivity in the 
midbrain by 76% and in the striatum by 32%. Providing evidence on the noninvasive 
neurotrophic delivery in brains halting the pathological progression could open new therapeutic 
strategies for the early treatment of neurodegenerative diseases and phenotypic reversal. 
 
For the final part of this dissertation, the immunomodulatory effects of FUS-induced BBB 
opening were investigated in two animal models of Alzheimer’s disease. Amyloid plaques and 
neurofibrillary tangles constitute the neuropathological hallmarks of the disease while tau 
pathology is associated with impaired neuronal activity and dementia. Repeated unilateral 
sonications in brains overexpressing tau pathology reduced the neuronal length affected by tau 
by 400 μm while maintaining neuronal integrity. Moreover, the 54.41% increase in the presence 
of immune cells and their engulfment with phosphorylated tau protein following sonications 
rightfully place them among the suggested mechanisms of pathological clearance. The series of 
events resulting in the interplay of intracellular tau with extracellular microglia have not been 
fully identified, yet it has been proposed that low molecular weight tau aggregates can be 
internalized and externalized transneuronally and/or transcellularly leading eventually to 
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tauopathy. It is therefore speculated that during this spreading phase, the tau misfolds could be 
captured by the immune cells12.  
 
Following such beneficial outcomes, it was pressing to investigate whether such results could be 
replicated in brains expressing full AD pathology. Therefore, 3xTg-AD mice, concurrently 
suffering from amyloid plaques and tau pathology, were employed to receive repeated bilateral 
sonications. Functional improvement was established in the Morris water maze followed by a 
58.31% decrease in the neuronal length affected by tau using immunohistochemistry and a 
27.2% reduction in tau levels shown by immunoblotting. Amyloid plaque population, volume 
and overall load were also decreased yet not significantly. Bilateral sonications are shown here 
for the first time to eliminate tau from the brain and improve the spatial memory of transgenic 
animals with complex AD phenotype. Given these observation, it is concluded that the 
synergistic action of tau reduction and the downstream effects of FUS-induced BBB opening 
triggered the spatial memory enhancement while the insignificant changes of the amyloid 
plaques are considered to have a diminished contribution. Translation of these findings to the 
clinic will have to address the compromised vascularity of AD patients’ brains. It is currently 
unknown how a disease-compromised BBB would interact with the microbubbles and the 
applied acoustic energy, given the vascular changes these patients encounter. However, the first 
completed phase I clinical trial recruiting AD patients did not report any vulnerability of these 
brains to the preferred sonication regime116. 
 
Overall, in this dissertation, we established an optimized targeting and detection protocol, pre-
clinical implementation of which confirmed its ameliorative effects as a drug-delivery adjuvant 
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or an immune response stimulant. The trajectory optimization resulting in improved sonication 
consistency and the equivalent immune response triggered by FUS-induced BBB opening in 
rodents and non-human primates (Pouliopoulos A. et al. submitted) as well as the improved 
human-disease approximation in animal models suggests a great potential in translating such 
observations in human subjects. 
 
Ongoing and future work 
The promising results of this thesis strongly indicate the potential of this method in the treatment 
of CNS diseases, especially in a clinical setting. The non-human primate studies along with the 
encouraging results in the Alzheimer’s studies served as the basis on which FDA approved the 
clinical trials using a neuronavigation-guided system to sonicate 6 AD patients. Despite the trial 
investigating the safety and feasibility profile of the module, amelioration of the pathology along 
the same line observed in rodent will be attempted in the future. During the planning session 
preceding the sonication, it is expected to identify the optimal sonication trajectory including a 
normal incidence angle and 3D evaluation of the trajectory will be performed. DTI is among the 
sequences that will be acquired, leading ultimately to the full substitution of Gd-enhanced 
imaging for such purposes. Increased DTI sensitivity will be accomplished with enhanced 
gradient strength and increased number of gradient directions that significantly increases the 
SNR and lowers the detection limit.   
 
Thus, DTI has been proven a valuable tool enabling the detection of the BBB opening in a 
contrast-free regime. Upon establishment of a diffusion direction from the blood-brain barrier 
opening with ultrasound, it is intriguing to investigate the local changes in metabolites. Recent 
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advances in magnetic resonance spectroscopy (MRS) have shown great potential in consistently 
detecting GABA levels among other molecules in mouse brains by the application of a MEGA-
PRESS sequence249. Therefore, investigation of the changes in GABA and other metabolites in 
mouse brains before and after the initiation of a BBB opening is proposed. 
 
The promising outcome measures of the studies focusing on drug delivery initiated a battery of 
experiments investigating the efficacy and feasibility of alternative administration routes of 
neurotrophic factors and antibodies in Parkinsonian animals suffering not only from the toxicity 
of MPTP but also from a-synuclein inclusions.  
 
As discussed in Chapter 5.2.4 behavioral improvement was not only observed in the transgenic 
group but in the non-transgenic group that received multiple sonications as well. This finding 
inspired a new study exploring the downstream effects of ultrasound on memory focusing on the 
activity of place and grid cells in response to the BBB opening. Moreover, recent findings 
indicating changes in functional connectivity as detected my fMRI studies should be embedded 
in the battery of sequences capable to detect pathological changes in the brain. It is also 
interesting to investigate whether such outcomes can be measured in the absence of BBB 
opening. Preliminary findings on microglia activation following different sonication regimes 
reveal a pronounced activation following sonication without microbubble administration as well 
as sonication at parameters beyond BBB detection at least with MRI’s sensitivity limit. In the 
last figure we show representative examples of the ipsilateral and contralateral sides of groups A-
D that received sonications. Briefly, group A encountered a large BBB opening volume beyond 
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kPa resulting in undetectable BBB opening and group D received ultrasound in the absence of 
microbubbles at 1 MPa. Despite the lack of BBB opening in groups C and D, shrinkage of the 
processes’ length and decrease in the number of microglia’s endpoints suggest pronounced 
activation in the hemisphere that received ultrasound similar to groups A and B. These findings 
are being replicated and expanded to understand the transcriptomic footprint of the acoustic 
energy at different levels250. 
 
Overall, the take home message of this work is that FUS, methodologically scrutinized and 
significantly improved herein, could induce BBB openings in different neurodegenerative 
models and initiate beneficial outcomes either by facilitating delivery of pharmacological agents 
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